aspirin has been researched along with Angina, Unstable in 498 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Angina, Unstable: Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.
Excerpt | Relevance | Reference |
---|---|---|
"Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 9.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
"The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events." | 9.15 | Apixaban with antiplatelet therapy after acute coronary syndrome. ( Alexander, JH; Atar, D; Bhatt, DL; Cools, F; Cornel, JH; Darius, H; De Caterina, R; Diaz, R; Flather, M; Geraldes, M; Goodman, S; Harrington, RA; He, Y; Huber, K; Husted, SE; James, S; Jansky, P; Keltai, M; Kilaru, R; Lawrence, J; Leiva-Pons, JL; Liaw, D; Lopes, RD; Lopez-Sendon, J; Mohan, P; Ogawa, H; Pais, P; Parkhomenko, A; Ruda, M; Ruzyllo, W; Verheugt, FW; Vinereanu, D; Wallentin, L; White, H, 2011) |
" Orbofiban, despite no significant excess risk of ICH, was not effective in preventing ischemic stroke or TIA." | 9.12 | Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. ( Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE, 2006) |
"Patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS) benefit from the early administration of aspirin, a small molecule glycoprotein IIb/IIIa inhibitor such as eptifibatide, and heparin." | 9.12 | Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin ( Armstrong, PW; Fitchett, DH; Goodman, SG; Langer, A; Mendelsohn, A; Tan, M, 2006) |
"Thrombocytopenia, though uncommon, was associated with orbofiban use and an increased risk of bleeding, but also death and MI." | 9.12 | Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. ( Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM, 2006) |
" The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial demonstrated the effectiveness of clopidogrel plus acetylsalicylic acid (ASA) compared with ASA alone in reducing cardiovascular events in patients with acute coronary syndromes and, in addition, patients undergoing percutaneous coronary intervention in the Percutaneous Coronary Intervention in CURE (PCI-CURE) trial." | 9.12 | Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial. ( Kolm, P; Mehta, SR; O'Brien, JA; Veledar, E; Weintraub, WS; Yuan, Y, 2007) |
"We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 9.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
"Aspirin therapy confers conclusive net benefits in the acute phase of evolving myocardial infarction, but no clear evidence of benefit from the long-term use of aspirin after acute myocardial infarction (AMI) has been shown in any single study." | 9.09 | Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. ( Hattori, R; Ishikawa, K; Masuda, Y; Miyazaki, S; Motomiya, T; Ogawa, H; Saito, M; Tamura, Y; Tanaka, H; Yamaguchi, T; Yasue, H, 1999) |
"Forty-three patients presenting with unstable angina or myocardial infarction were randomised double blind to warfarin [target international normalised ratio (INR), 2." | 9.09 | Coronary artery flow ten weeks after myocardial infarction or unstable angina: effects of combined warfarin and aspirin therapy. ( Stewart, RA; Williams, MJ, 1999) |
"The rate of death, myocardial infarction, and urgent revascularization at days 8 and 43 after randomization was compared among patients who received aspirin within the week before randomization with those who did not receive aspirin in the TIMI 11B trial." | 9.09 | Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. ( Antman, EM; Bozovich, GE; Gurfinkel, EP; Marcos, E; Mautner, B; McCabe, CH; Santopinto, J; Torres, V, 2001) |
" We evaluated tirofiban, a specific inhibitor of the platelet glycoprotein IIb/IIIa receptor, in the treatment of unstable angina and non-Q-wave myocardial infarction." | 9.08 | Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. ( , 1998) |
"The aim of this trial was to compare the efficacy of combination antithrombotic therapy with a prostacyclin-sparing aspirin plus anticoagulation versus conventional aspirin plus anticoagulation, when added to antianginal therapy, in patients with unstable angina or non-Q wave myocardial infarction already being treated with aspirin." | 9.07 | Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. The Antithrombotic Therapy in Acute Coronary Syndromes Research Group. ( Adams, PC; Chamberlain, D; Cohen, M; Fox, KA; Fuster, V; Kronmal, R; Parry, G; Wieczorek, I; Xiong, J, 1994) |
"This study compared the effects of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina." | 9.07 | Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. ( Cunningham, D; Fox, K; Hendry, G; Holdright, D; Hubbard, W; Patel, D; Sutton, G; Thomas, R, 1994) |
"This study documents that heparin prevents myocardial infarction better than aspirin during the acute phase of unstable angina." | 9.07 | Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. ( de Guise, P; Juneau, M; McCans, J; Qiu, S; Théroux, P; Waters, D, 1993) |
"In this study, 796 men with unstable coronary artery disease (that is, unstable angina or non-Q wave myocardial infarction) were randomized to double-blind placebo-controlled treatment with aspirin (75 mg/day)." | 9.07 | Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in ( Wallentin, LC, 1991) |
"Both experimental and clinical studies suggest that the prehospital administration of aspirin may be beneficial in patients with unstable angina and acute myocardial infarction." | 8.79 | Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. ( Eisenberg, MJ; Topal, EJ, 1996) |
"To estimate the risk of myocardial infarction (MI) and death in patients with unstable angina who are treated with aspirin plus heparin compared with patients treated with aspirin alone." | 8.79 | Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. ( Grady, D; Oler, A; Oler, J; Whooley, MA, 1996) |
"The use of aspirin and thrombolytic agents in the management of acute myocardial infarction is now accepted as standard clinical practice, but not all patients with heart attack are suitable for such therapy." | 8.78 | Aspirin and thrombolytic therapy in the management of acute myocardial infarction. ( Hockings, B, 1990) |
"One-year treatment with clopidogrel in addition to aspirin is a cost-effective treatment option for secondary prevention in patients with acute coronary syndrome without ST-segment elevation in Greece." | 7.78 | Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. ( Fragoulakis, V; Kourlaba, G; Maniadakis, N, 2012) |
"In this study, we aimed to assess the factors associated with laboratory-defined aspirin resistance and the relationship of this laboratory-defined aspirin resistance with thrombolysis in myocardial infarction risk score, markers of cardiac necrosis, and inflammatory and thrombotic risk factors in patients with unstable angina or non-ST elevation myocardial infarction." | 7.75 | The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes. ( Acikel, S; Aydinalp, A; Bal, U; Kaynar, G; Muderrisoglu, H; Ozin, B; Yildirir, A, 2009) |
"Recent studies have suggested that low-dose aspirin has preserved benefit with less bleeding compared with standard-dose aspirin when given with or without clopidogrel in patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACSs)." | 7.74 | Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. ( Cannon, CP; Gibler, WB; Milford-Beland, S; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tickoo, S, 2007) |
"To compare the efficacy of intravenous versus oral aspirin use in patients with acute coronary syndrome (ACS)." | 7.74 | [Efficacy of intravenous aspirin use in patients with acute coronary syndrome]. ( Shen, LH; Yang, M; Zhao, Y, 2007) |
"Aspirin has been used for secondary prevention of myocardial infarction (MI) in individuals with coronary disease." | 7.74 | Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers. ( Eskola, M; Karhunen, PJ; Mikkelsson, J; Niemela, K; Nikus, K, 2008) |
"Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI." | 7.73 | [Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006) |
"We report a case of a 76-year-old-man who developed spontaneous hemarthrosis of his right knee following clopidogrel-aspirin treatment." | 7.72 | Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment. ( Behrens, P; Bernotat, J; Böhm, S; Gille, J; Löhr, JF, 2003) |
"Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease." | 7.72 | Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004) |
"Aspirin's role in the management of suspected myocardial infarction has been well established." | 7.71 | A study of the use of aspirin by general practitioners in suspected myocardial infarction. ( O'Shea, EB, 2001) |
" The CURE trial shows that clopidogrel in addition to aspirin achieves this double goal, with a 20% relative risk reduction in the primary composite endpoint of cardiovascular death, myocardial infarction or stroke in the first 30 days." | 7.71 | [Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial]. ( Valentín, V, 2001) |
"SYMPHONY (Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary syndromes) was a randomized, double-blind, aspirin-controlled trial with 2 concentration regimens of sibrafiban, an oral peptidomimetic GP IIb/IIIa antagonist, for long-term treatment instead of aspirin in patients after an ACS." | 7.70 | Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) ( Newby, LK, 1999) |
"We conducted a retrospective case-control study to compare the frequency of myocardial infarction (MI) or unstable angina (UA) precipitated by aspirin-induced upper gastrointestinal (GI) bleeding among patients with and without ischemic heart disease(IHD), and to determine whether the risk of MI or UA is related to the hemoglobin level on admission." | 7.69 | Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction. ( Amital, H; Bar Dayan, Y; Levy, Y; Shoenfeld, Y, 1996) |
"We present a series of fifteen patients treated with low dose aspirin for secondary prevention of ischemic heart disease who had upper GI bleeding and were admitted to our hospital because of unstable angina or myocardial infarction." | 7.69 | Aspirin for prevention of myocardial infarction. A double-edged sword. ( Amital, H; Bar-Dayan, Y; Levy, Y; Shoenfeld, Y, 1997) |
"Platelet functional parameters (platelet aggregation, blood circulating reversibly and irreversibly aggregated platelet complexes, thromboxane B2, 6-keto-PGF1 alpha) were examined in unstable angina treated with aspirin in a daily dose of 320 mg in relation to the outcome of the disease: Group 1, stabilization and Group 2, evolving myocardial infarction." | 7.68 | [Development of myocardial infarction in aspirin-treated unstable angina pectoris. Repeated studies of platelet aggregation and of the thromboxane-prostacyclin system]. ( Shalaev, SV, 1992) |
"We examined the prevalence and medical treatment of hypertension among 15,904 ACS patients randomized in the SYMPHONY and 2nd SYMPHONY trials." | 6.71 | Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical ( Armstrong, PW; Aylward, PE; Bhapkar, MV; Frazier, CG; Klein, WW; Kristinsson, A; McGuire, DK; Newby, LK; Sadowski, Z; Shah, SH; Weaver, WD, 2005) |
"When ticlopidine was given for 72 hours, TF levels were similar to normal laboratory values both in stable and unstable patients." | 6.69 | Effect of aspirin and ticlopidine on plasma tissue factor levels in stable and unstable angina pectoris. ( Ariëns, RA; Bernies, M; Bossi, IM; Brambilla, GM; Donatelli, F; Fajadet, J; Gregorini, L; Marco, I; Marco, J; Mari, D; Romano, SM; Somalvico, F, 2000) |
"In secondary-prevention trials to treat unstable angina, which were performed in USA and Canada, the number of non-fatal myocardial infarctions was reduced by about 50 per cent." | 6.38 | Anti-thrombotic drugs in the treatment of coronary heart disease: the present situation with aspirin. ( Born, GV, 1990) |
"The mainstay of treatment for unstable coronary artery disease (UCAD) currently consists of antithrombotic therapy with aspirin plus unfractionated heparin (UFH), together with anti-ischemic treatment with beta blockers and nitrates." | 6.19 | Long-term management--the way forward? ( Wallentin, L, 2000) |
" On the basis of present information it is evident that, in addition to heparin, all patients suffering from suspected acute myocardial infarction should receive immediate low dose aspirin which should be continued for one to six months." | 6.16 | Restoration of flow in acute coronary obstructive syndromes: consequences of different management strategies. ( McGregor, M; Silberberg, JS, 1989) |
" The use of aspirin in unstable angina in the Canadian Aspirin trial was key to establishing the benefit of aspirin in acute coronary syndrome." | 5.22 | The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey. ( Bainey, KR; Marquis-Gravel, G; Mehta, SR; Robert-Halabi, M; Tanguay, JF, 2022) |
"Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 5.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
"Patients with medically managed unstable angina or non-ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS trial (2008 to 2011) comparing clopidogrel vs prasugrel." | 5.16 | Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. ( Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C, 2012) |
"The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events." | 5.15 | Apixaban with antiplatelet therapy after acute coronary syndrome. ( Alexander, JH; Atar, D; Bhatt, DL; Cools, F; Cornel, JH; Darius, H; De Caterina, R; Diaz, R; Flather, M; Geraldes, M; Goodman, S; Harrington, RA; He, Y; Huber, K; Husted, SE; James, S; Jansky, P; Keltai, M; Kilaru, R; Lawrence, J; Leiva-Pons, JL; Liaw, D; Lopes, RD; Lopez-Sendon, J; Mohan, P; Ogawa, H; Pais, P; Parkhomenko, A; Ruda, M; Ruzyllo, W; Verheugt, FW; Vinereanu, D; Wallentin, L; White, H, 2011) |
"Acetylsalicylic acid (aspirin) is widely used in the secondary prevention of coronary artery disease." | 5.14 | Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting. ( Jannati, M; Khalili, A; Kojuri, J; Mahboodi, A; Mahmoody, Y; Zangbar Sabegh, B, 2010) |
"Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention, but it is associated with an increased risk of major bleeding." | 5.13 | Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys ( Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD, 2008) |
" Orbofiban, despite no significant excess risk of ICH, was not effective in preventing ischemic stroke or TIA." | 5.12 | Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. ( Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE, 2006) |
"Patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS) benefit from the early administration of aspirin, a small molecule glycoprotein IIb/IIIa inhibitor such as eptifibatide, and heparin." | 5.12 | Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin ( Armstrong, PW; Fitchett, DH; Goodman, SG; Langer, A; Mendelsohn, A; Tan, M, 2006) |
"Aspirin can inhibit inflammatory reactions and platelet aggregation, but little is known about the effects of the combination of aspirin plus clopidogrel, a new antiplatelet agent, on inflammation." | 5.12 | Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. ( Chen, YG; Ji, QS; Li, RJ; Lü, RJ; Sun, Y; Xu, F; Zhang, Y, 2006) |
"Thrombocytopenia, though uncommon, was associated with orbofiban use and an increased risk of bleeding, but also death and MI." | 5.12 | Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. ( Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM, 2006) |
"Aspirin resistance may increase up to more then threefold the risk of major cardiovascular events (MACE) in patients with stable coronary artery disease." | 5.12 | The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Ozcan, M; Pamukcu, B; Umman, B, 2006) |
" The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial demonstrated the effectiveness of clopidogrel plus acetylsalicylic acid (ASA) compared with ASA alone in reducing cardiovascular events in patients with acute coronary syndromes and, in addition, patients undergoing percutaneous coronary intervention in the Percutaneous Coronary Intervention in CURE (PCI-CURE) trial." | 5.12 | Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial. ( Kolm, P; Mehta, SR; O'Brien, JA; Veledar, E; Weintraub, WS; Yuan, Y, 2007) |
"We evaluated whether the use of glycoprotein IIb/IIIa receptor inhibitors, in addition to heparin and aspirin, imparts an incremental benefit in a subgroup of patients with acute coronary syndromes (ACS) who had congestive heart failure (CHF) symptoms at presentation." | 5.11 | Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. ( Harrington, RA; Hochman, JS; Houghtaling, PL; Jaber, WA; Marso, SP; Menon, V; Prior, DL; Simoons, ML; Srichai, MB, 2004) |
" Platelet-leukocyte conjugate formation (induced by thrombin receptor activating peptide (TRAP)) and platelet aggregation (induced by ADP and arachidonic acid) were assessed in 30 patients with unstable angina or non-ST elevation myocardial infarction." | 5.11 | Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. ( Bolton, ED; Braunstein, JB; Chiles, KA; Faraday, N; Gerstenblith, G; Heldman, AW; Schulman, SP, 2004) |
"In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial, 12 562 patients were randomized to clopidogrel or placebo in addition to aspirin, and the primary outcome was cardiovascular (CV) death, myocardial infarction (MI), or stroke." | 5.11 | Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. ( Fox, KA; Gersh, BJ; Lakkis, N; Mehta, SR; Peters, R; Yusuf, S; Zhao, F, 2004) |
"We evaluated stroke incidence, subtypes, and outcomes, in addition to demographics and clinical risk characteristics associated with stroke among patients enrolled in the Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY) and 2nd SYMPHONY trials." | 5.11 | Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. ( Bhapkar, MV; Califf, RM; Graffagnino, C; Kassem-Moussa, H; Mahaffey, KW; Newby, LK; Sila, CA; Simes, RJ; Tasissa, G; White, HD, 2004) |
" The purpose of the study was to evaluate the effects of tirofiban on clinical stabilization parameters in patients with unstable angina (UA) and non-Q-wave myocardial infarction (MI)." | 5.10 | Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction. ( Cakmak, M; Cam, N; Okmen, E; Tartan, Z, 2003) |
"We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 5.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
"Despite the use of heparin, aspirin, and other antiplatelet agents, acute coronary syndrome patients without ST-segment elevation remain at risk of cardiovascular thrombotic events." | 5.10 | Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. ( Altman, R; Berman, SG; Del Rio, F; Gonzalez, C; Lopez, R; Luciardi, HL; Muntaner, J, 2002) |
"Aspirin therapy confers conclusive net benefits in the acute phase of evolving myocardial infarction, but no clear evidence of benefit from the long-term use of aspirin after acute myocardial infarction (AMI) has been shown in any single study." | 5.09 | Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. ( Hattori, R; Ishikawa, K; Masuda, Y; Miyazaki, S; Motomiya, T; Ogawa, H; Saito, M; Tamura, Y; Tanaka, H; Yamaguchi, T; Yasue, H, 1999) |
"Forty-three patients presenting with unstable angina or myocardial infarction were randomised double blind to warfarin [target international normalised ratio (INR), 2." | 5.09 | Coronary artery flow ten weeks after myocardial infarction or unstable angina: effects of combined warfarin and aspirin therapy. ( Stewart, RA; Williams, MJ, 1999) |
"Despite use of heparin and aspirin, 5-10% of patients with unstable angina develop myocardial infarction (MI) or refractory angina in the hospital." | 5.09 | Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial. ( Yusuf, S, 1999) |
"The long-term risk of myocardial infarction (MI) or death remains high in patients with unstable angina, despite the use of aspirin." | 5.09 | Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. ( , 2001) |
"The rate of death, myocardial infarction, and urgent revascularization at days 8 and 43 after randomization was compared among patients who received aspirin within the week before randomization with those who did not receive aspirin in the TIMI 11B trial." | 5.09 | Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. ( Antman, EM; Bozovich, GE; Gurfinkel, EP; Marcos, E; Mautner, B; McCabe, CH; Santopinto, J; Torres, V, 2001) |
" At 5 hospitals, 39 patients with unstable angina or non-Q wave myocardial infarction, who were receiving aspirin and heparin, were administered intravenous AR-C69931MX with stepped dose increments over 3 h to a plateau of either 2 microg/kg/min for 21 h (Part 1; n = 12) or up to 69 h (Part 2; n = 13) or 4 microg/kg/min for up to 69 h (Part 3: n = 14)." | 5.09 | Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ( Oldroyd, KG; Storey, RF; Wilcox, RG, 2001) |
"In patients with unstable angina and myocardial infarction without ST-segment elevation who were treated with the glycoprotein IIb/IIIa inhibitor tirofiban, the use of an early invasive strategy significantly reduced the incidence of major cardiac events." | 5.09 | Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. ( Braunwald, E; Cannon, CP; DeLucca, PT; Demopoulos, LA; DiBattiste, PM; Frey, MJ; Gibson, CM; Lakkis, N; Neumann, FJ; Robertson, DH; Vicari, R; Weintraub, WS, 2001) |
"The authors examined the bleeding complications in 75 patients who received acenocoumarol and acetylsalicylic acid combined therapy." | 5.08 | [Adverse effects of combined use of acenocoumarol and acetylsalicylic acid after myocardial infarct and unstable angina]. ( Farkas, A; Sámóczi, M; Sipos, E; Tarján, J, 1995) |
"1506 patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) took part in a double-blind trial and were randomly assigned subcutaneous dalteparin (Fragmin; 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days then 7500 IU once daily for the next 35-45 days) or placebo injections." | 5.08 | Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. ( , 1996) |
"Our results add to previous evidence suggesting that the low-molecular-weight heparin dalteparin administered by twice-daily subcutaneous injection may be an alternative to unfractionated heparin in the acute treatment of unstable angina or non-Q-wave myocardial infarction." | 5.08 | Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) ( Buchwald, A; Hillis, SE; Klein, W; Ludwig, K; Monrad, S; Olaisson, E; Sanz, G; Turpie, AG; Undeland, S; van der Meer, J, 1997) |
"Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase." | 5.08 | A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. ( Bigonzi, F; Califf, RM; Cohen, M; Demers, C; Fox, KA; Fromell, GJ; Goodman, S; Gurfinkel, EP; Langer, A; Premmereur, J; Turpie, AG, 1997) |
" We evaluated tirofiban, a specific inhibitor of the platelet glycoprotein IIb/IIIa receptor, in the treatment of unstable angina and non-Q-wave myocardial infarction." | 5.08 | Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. ( , 1998) |
"In a multicenter trial of antithrombotic therapy in unstable angina or non-Q wave myocardial infarction, 358 patients admitted within 48 h of chest pain were randomized to antithrombotic therapy with either 1) aspirin alone, or 2) aspirin plus heparin followed by aspirin plus warfarin, and were prospectively followed up for 12 weeks." | 5.07 | Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. ( Adams, PC; Chamberlain, D; Chesebro, JH; Cohen, M; Fox, KA; Fuster, V; McBride, R; Parry, G; Wieczorek, I; Xiong, J, 1993) |
"The aim of this trial was to compare the efficacy of combination antithrombotic therapy with a prostacyclin-sparing aspirin plus anticoagulation versus conventional aspirin plus anticoagulation, when added to antianginal therapy, in patients with unstable angina or non-Q wave myocardial infarction already being treated with aspirin." | 5.07 | Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. The Antithrombotic Therapy in Acute Coronary Syndromes Research Group. ( Adams, PC; Chamberlain, D; Cohen, M; Fox, KA; Fuster, V; Kronmal, R; Parry, G; Wieczorek, I; Xiong, J, 1994) |
"This study compared the effects of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina." | 5.07 | Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. ( Cunningham, D; Fox, K; Hendry, G; Holdright, D; Hubbard, W; Patel, D; Sutton, G; Thomas, R, 1994) |
"This study documents that heparin prevents myocardial infarction better than aspirin during the acute phase of unstable angina." | 5.07 | Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. ( de Guise, P; Juneau, M; McCans, J; Qiu, S; Théroux, P; Waters, D, 1993) |
"The purpose of this study was to compare combination antithrombotic therapy with aspirin plus anticoagulation versus aspirin alone, when added to conventional antianginal therapy in patients with unstable rest angina or non-Q-wave myocardial infarction who were nonprior aspirin users." | 5.07 | Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. ( Adams, PC; Chamberlain, D; Chesebro, JH; Cohen, M; Fox, KA; Keller, C; Parry, G; Strain, J; Wieczorek, I; Xiong, J, 1994) |
"In this study, 796 men with unstable coronary artery disease (that is, unstable angina or non-Q wave myocardial infarction) were randomized to double-blind placebo-controlled treatment with aspirin (75 mg/day)." | 5.07 | Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in ( Wallentin, LC, 1991) |
"We tested the usefulness of aspirin (325 mg twice daily), heparin (1000 units per hour by intravenous infusion), and a combination of the two in the early management of acute unstable angina pectoris in a double-blind, randomized, placebo-controlled trial involving 479 patients." | 5.06 | Aspirin, heparin, or both to treat acute unstable angina. ( deGuise, P; Joly, P; Juneau, M; Latour, JG; Lévy, G; McCans, J; Ouimet, H; Pelletier, E; Stasiak, J; Théroux, P, 1988) |
"A randomized, double-blind clinical trial in 1266 men with unstable angina showed that 324 mg of aspirin daily for 12 weeks reduced the incidence of myocardial infarction by 51% (p = ." | 5.05 | Unstable angina: status of aspirin and other forms of therapy. ( Lewis, HD, 1985) |
"In aspirin-treated patients with acute coronary syndromes without ST-segment elevation unfractionated heparin (UFH) or low molecular weight heparin (LMWH) treatment < 7 days significantly reduce the risk of acute myocardial infarction (AMI), and LMWH furthermore reduces revascularisation." | 4.86 | [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]. ( Husted, SE; Nielsen, HK, 2010) |
" Irrespective of International normalized ratio (INR), A+W did not significantly affect the risk of major adverse events (MAE: all cause death, non-fatal myocardial infarction, and non-fatal thrombo-embolic stroke) when compared with aspirin alone [OR 0." | 4.83 | Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. ( Andreotti, F; Biondi-Zoccai, GG; Crea, F; Testa, L, 2006) |
" The CURE study evaluated the efficacy and safety of clopidogrel on top of acetylsalicylic acid (ASA) versus standard therapy (including ASA) in over 12,000 patients with unstable angina or non-ST-segment elevation myocardial infarction (MI)." | 4.82 | Recent clinical trial results with antiplatelet therapy: implications in stroke prevention. ( Teal, PA, 2004) |
" In patients with NSTEMI/UA, beta-blockers, nitrates and calcium antagonists will improve chest pain, and invasive management of ACS is indicated in < 48 h, if risk factors are present." | 4.82 | [Acute chest pain]. ( Perings, C; Trappe, HJ, 2005) |
" Beta-blockers, nitrates, and calcium-channel blockers are useful for antiischemic therapy in patients with acute coronary syndromes." | 4.81 | [Acute coronary syndromes: an update. I. Pathogenesis and drug therapy]. ( Auer, J; Berent, R; Eber, B; Maurer, E; Mayr, H; Weber, T, 2001) |
" coronary angioplasty (PTCA) with or without stent implantation), and in unstable angina/non-ST-segment elevation myocardial infarction, the risk of acute vessel occlusion by thrombosis is high in spite of treatment with aspirin and heparin." | 4.81 | Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction. ( Bosch, X; Marrugat, J, 2001) |
" In the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) Trial, clopidogrel (clopidogrel bisulphate) was superior to acetylsalicylic acid (ASA) in reducing the combined risk of ischaemic stroke (IS), myocardial infarction (MI) or vascular death in patients with symptomatic atherosclerosis." | 4.81 | From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. ( Hacke, W, 2002) |
" On the contrary, the initial treatment with clopidogrel in addition to aspirin and anticoagulation led to a 20% relative risk reduction for an endpoint of death, myocardial infarction and stroke in the CURE trial." | 4.81 | [Modern therapy in acute coronary syndrome]. ( Blankenberg, S; Espinola-Klein, C; Meyer, J; Rupprecht, HJ, 2002) |
"Antithrombotic and antiplatelet agents, particularly unfractionated heparin and aspirin, are longstanding therapeutic mainstays for acute coronary syndromes such as unstable angina and non-Q-wave myocardial infarction (MI)." | 4.80 | Anticoagulants in acute coronary syndromes. ( Turpie, AG, 1999) |
"Aspirin, a potent platelet inhibitor, is widely used in patients with cardiovascular diseases." | 4.80 | [Aspirin and prevention of cardiovascular risk]. ( Gabriel Steg, P; Karila-Cohen, D, 2000) |
"In the medical literature reports are accumulating a number of case reports suggesting the potential efficacy and safety of the combination of low-dose aspirin and warfarin to improve the efficacy of antithrombotic therapy in several clinical conditions, ranging from unstable angina to myocardial infarction." | 4.79 | [The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?]. ( Casazza, F; Cimminiello, C; Soncini, M, 1995) |
" The recent clinical reports suggest that there is a narrower window of safety with recombinant hirudin than initially thought particularly when it is used in conjunction with thrombolytic agents and aspirin in acute myocardial infarction." | 4.79 | Advances in antithrombotic therapy: novel agents. ( Hirsh, J; Turpie, AG; Weitz, JI, 1995) |
"Both experimental and clinical studies suggest that the prehospital administration of aspirin may be beneficial in patients with unstable angina and acute myocardial infarction." | 4.79 | Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. ( Eisenberg, MJ; Topal, EJ, 1996) |
"To estimate the risk of myocardial infarction (MI) and death in patients with unstable angina who are treated with aspirin plus heparin compared with patients treated with aspirin alone." | 4.79 | Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. ( Grady, D; Oler, A; Oler, J; Whooley, MA, 1996) |
"The formation of the proischemic and prothrombotic thromboxane A2 (TXA2) and of its functional antagonist prostacyclin is increased in patients with unstable angina and myocardial infarction." | 4.78 | Pathophysiological role of thromboxane A2 and pharmacological approaches to its inhibition. ( Hornberger, W; Patscheke, H; Zehender, H, 1990) |
"The use of aspirin and thrombolytic agents in the management of acute myocardial infarction is now accepted as standard clinical practice, but not all patients with heart attack are suitable for such therapy." | 4.78 | Aspirin and thrombolytic therapy in the management of acute myocardial infarction. ( Hockings, B, 1990) |
" These studies, in conjunction with recent histopathologic studies demonstrating plaque defects and overlying thrombosis in patients with unstable ischemia and sudden death, suggest a common mechanism for unstable angina and myocardial infarction and strongly support the rationale for antithrombotic therapy with heparin and with aspirin in the management of patients with unstable angina." | 4.77 | Thrombosis in unstable angina: angiographic aspects. ( Cowley, MJ; DiSciascio, G; Rehr, RB, 1987) |
"The present study concluded that long-term dual antiplatelet therapy including clopidogrel and aspirin could decrease the risks of all-cause death, myocardial infarction." | 4.02 | Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database. ( Guo, L; Man, F; Pan, Q; Wang, W; Wang, X; Zhang, J; Zhang, L, 2021) |
"Antithrombotic treatment of unstable angina is a highly controversial subject." | 3.79 | [Antithrombotic agents in unstable angina. Review of clinical trials]. ( Habis, M; Morice, MC, 1998) |
"One-year treatment with clopidogrel in addition to aspirin is a cost-effective treatment option for secondary prevention in patients with acute coronary syndrome without ST-segment elevation in Greece." | 3.78 | Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. ( Fragoulakis, V; Kourlaba, G; Maniadakis, N, 2012) |
"Pre-hospitalization medication such as aspirin and nitrates has been shown to affect the mode of presentation in acute coronary syndrome (ACS)." | 3.77 | Differences in the mode of presentation for acute coronary syndrome by pre-hospitalization medication, in relation to coronary risk factors, East-Osaka acute coronary syndrome (EACS) registry. ( Hoshida, S; Iwasaka, J; Iwasaka, T; Kijima, Y; Lim, YJ; Yuasa, F, 2011) |
"In this study, we aimed to assess the factors associated with laboratory-defined aspirin resistance and the relationship of this laboratory-defined aspirin resistance with thrombolysis in myocardial infarction risk score, markers of cardiac necrosis, and inflammatory and thrombotic risk factors in patients with unstable angina or non-ST elevation myocardial infarction." | 3.75 | The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes. ( Acikel, S; Aydinalp, A; Bal, U; Kaynar, G; Muderrisoglu, H; Ozin, B; Yildirir, A, 2009) |
" Poisson regression models were used to assess whether CAM use was independently associated with lower rates of aspirin, beta-blocker, and statin use in 596 patients with established coronary artery disease (CAD)." | 3.74 | Self-reported use of complementary and alternative medicine in patients with previous acute coronary syndrome. ( Banerjee, S; Buchanan, DM; Decker, C; Huddleston, J; Jones, A; Kosiborod, M; Spertus, JA; Stoner, C, 2007) |
"Recent studies have suggested that low-dose aspirin has preserved benefit with less bleeding compared with standard-dose aspirin when given with or without clopidogrel in patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACSs)." | 3.74 | Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. ( Cannon, CP; Gibler, WB; Milford-Beland, S; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tickoo, S, 2007) |
"Platelet function analyses, which included measures of platelet aggregation and activation, were performed in 173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel." | 3.74 | Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M, 2007) |
"To compare the efficacy of intravenous versus oral aspirin use in patients with acute coronary syndrome (ACS)." | 3.74 | [Efficacy of intravenous aspirin use in patients with acute coronary syndrome]. ( Shen, LH; Yang, M; Zhao, Y, 2007) |
"Aspirin has been used for secondary prevention of myocardial infarction (MI) in individuals with coronary disease." | 3.74 | Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers. ( Eskola, M; Karhunen, PJ; Mikkelsson, J; Niemela, K; Nikus, K, 2008) |
" Hospital charts review revealed key information for clinical variables, smoking, obesity and use of aspirin at admission." | 3.74 | Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database. ( Aguado, J; Castellsague, J; Perez-Gutthann, S; Stang, MR; Tomas, L; Varas-Lorenzo, C, 2008) |
" The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel." | 3.73 | A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ( Heidenreich, PA; Schleinitz, MD, 2005) |
"Utilizing data from the Global Registry of Acute Coronary Events, we studied 15 693 patients admitted with non-ST-segment elevation myocardial infarction (MI) or unstable angina, dividing them according to discharge medications: aspirin alone (group I); aspirin + clopidogrel (group II); aspirin + statin (group III); aspirin + clopidogrel + statin (group IV)." | 3.73 | Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. ( Agnelli, G; Dabbous, OH; Dibenedetto, D; Eagle, KA; Gore, JM; Kline-Rogers, EM; Lim, MJ; Mehta, RH; Spencer, FA, 2005) |
"Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI." | 3.73 | [Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006) |
"We report a case of a 76-year-old-man who developed spontaneous hemarthrosis of his right knee following clopidogrel-aspirin treatment." | 3.72 | Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment. ( Behrens, P; Bernotat, J; Böhm, S; Gille, J; Löhr, JF, 2003) |
"We performed a retrospective analysis of the Mayo Clinic PCI database and identified 66 consecutive patients who were discharged from hospital after PCI between January 2000 and August 2002 (inclusive) receiving a combination of dual antiplatelet therapy (aspirin and clopidogrel) and systemic anticoagulation (warfarin) to determine the incidence of bleeding and other clinical events during the treatment period." | 3.72 | Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. ( Berger, PB; Burger, K; Fasseas, P; Holmes, DR; Melby, S; Orford, JL; Steinhubl, SR, 2004) |
"The possible additive antiplatelet effects of aspirin and clopidogrel have been explored in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) studies." | 3.72 | Long-term combination therapy with aspirin and clopidogrel. ( Cheung, BM; Cheung, G; Kumana, CR; Lauder, IJ, 2004) |
"Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease." | 3.72 | Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004) |
" The coronary reperfusion was achieved in 59% patients with acute myocardial infarction (MI) treated with thrombolysis, but in 27% patients with MI treated only heparin and aspirin." | 3.71 | [Prospective analysis of conservative treatment of acute coronary syndrome]. ( Batyraliev, TA; Daniiarov, BS; Niiazova-Karben, ZA; Pershukov, IV; Pia, IuV; Preobrazhenskiĭ, DV; Sidorenko, BA, 2002) |
"Aspirin's role in the management of suspected myocardial infarction has been well established." | 3.71 | A study of the use of aspirin by general practitioners in suspected myocardial infarction. ( O'Shea, EB, 2001) |
"ASPIRIN AND HEPARIN: In several studies aspirin has been found to be very effective in unstable angina pectoris reducing fatal and non-fatal myocardial infarction by 50-70%." | 3.71 | [Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions]. ( Huber, K; Niessner, A; Niessner, H, 2001) |
" The CURE trial shows that clopidogrel in addition to aspirin achieves this double goal, with a 20% relative risk reduction in the primary composite endpoint of cardiovascular death, myocardial infarction or stroke in the first 30 days." | 3.71 | [Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial]. ( Valentín, V, 2001) |
"The current standard of care for patients with non-ST-segment elevation acute coronary syndromes (ACS) includes antithrombotic therapy with aspirin and heparin." | 3.71 | Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ( Antman, EM; Ball, SP; Becker, RC; Gibson, M; Murphy, SA; Rush, JE; Sanderink, G; Spencer, FA, 2002) |
"Aspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina." | 3.70 | New antiplatelet agents. ( Ellis, CJ; French, JK; White, HD, 1998) |
"SYMPHONY (Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary syndromes) was a randomized, double-blind, aspirin-controlled trial with 2 concentration regimens of sibrafiban, an oral peptidomimetic GP IIb/IIIa antagonist, for long-term treatment instead of aspirin in patients after an ACS." | 3.70 | Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) ( Newby, LK, 1999) |
"(1) Enoxaparin and dalteparin are the only low-molecular-weight heparins so far approved for the treatment of unstable angina and non Q-wave myocardial infarction." | 3.70 | Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin. ( , 1999) |
" We analyzed the early (30 days) and late outcome of a cohort of 459 consecutive patients who underwent stent placement with ticlopidine and aspirin as antithrombotic regimen according to the presence (group 1, n = 151) or absence (group 2, n = 308) of unstable angina at rest (Braunwald classes II and III)." | 3.70 | Long-term outcome in patients treated by intracoronary stenting with ticlopidine and aspirin, and deleterious prognostic role of unstable angina pectoris. ( Alla, F; Angioi, M; Cherrier, F; Danchin, N; Gangloff, C; Grentzinger, A; Houplon, P; Juillière, Y; Preiss, JP; Rodriguez, RM; Sunthorn, H, 2000) |
"(1) Aspirin reduces acute-phase mortality after myocardial infarction, and also reduces the risk of myocardial infarction and death in patients with unstable angina." | 3.70 | Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention. ( , 2000) |
"The present study was designed to investigate whether the prior use of aspirin could influence the severity of the manifestation of acute coronary artery syndromes, given the well-documented observations that aspirin can prevent myocardial infarction, stroke, and death in cardiovascular disease." | 3.69 | Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes. ( Garcia-Dorado, D; Oliveras, J; Sambola, A; Santos, M; Soler Soler, J; Théroux, P; Tornos, P, 1995) |
"We conducted a retrospective case-control study to compare the frequency of myocardial infarction (MI) or unstable angina (UA) precipitated by aspirin-induced upper gastrointestinal (GI) bleeding among patients with and without ischemic heart disease(IHD), and to determine whether the risk of MI or UA is related to the hemoglobin level on admission." | 3.69 | Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction. ( Amital, H; Bar Dayan, Y; Levy, Y; Shoenfeld, Y, 1996) |
"We present a series of fifteen patients treated with low dose aspirin for secondary prevention of ischemic heart disease who had upper GI bleeding and were admitted to our hospital because of unstable angina or myocardial infarction." | 3.69 | Aspirin for prevention of myocardial infarction. A double-edged sword. ( Amital, H; Bar-Dayan, Y; Levy, Y; Shoenfeld, Y, 1997) |
"Platelet functional parameters (platelet aggregation, blood circulating reversibly and irreversibly aggregated platelet complexes, thromboxane B2, 6-keto-PGF1 alpha) were examined in unstable angina treated with aspirin in a daily dose of 320 mg in relation to the outcome of the disease: Group 1, stabilization and Group 2, evolving myocardial infarction." | 3.68 | [Development of myocardial infarction in aspirin-treated unstable angina pectoris. Repeated studies of platelet aggregation and of the thromboxane-prostacyclin system]. ( Shalaev, SV, 1992) |
"We randomly divided 100 unstable angina pectoris (UAP) patients into two groups: the trial group received Sulfotanshinone Sodium Injection (SSI) 60 mg combined with a loading dose of 300 mg aspirin and a maintenance dose of 100 mg of aspirin plus baseline therapy, and the control group received the same doses of aspirin and baseline therapy." | 2.74 | Sulfotanshinone Sodium Injection could decrease fibrinogen level and improve clinical outcomes in patients with unstable angina pectoris. ( Liu, Y; Liu, YF; Yan, FF; Zhao, YX, 2009) |
"Myocardial infarction was more frequent in the early invasive strategy group (106 [18." | 2.73 | Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. ( Cornel, JH; de Winter, RJ; Hirsch, A; Tijssen, JG; Verheugt, FW; Windhausen, F, 2007) |
"0001), and major adverse cardiac events (8." | 2.73 | Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). ( Holmes, DR; Kuntz, RE; Leon, MB; Mishkel, G; Moses, JW; Popma, JJ; Raizner, AE; Satler, LF; Teirstein, PS; Wang, P; Weisz, G; Wilensky, RL, 2007) |
"We examined the prevalence and medical treatment of hypertension among 15,904 ACS patients randomized in the SYMPHONY and 2nd SYMPHONY trials." | 2.71 | Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical ( Armstrong, PW; Aylward, PE; Bhapkar, MV; Frazier, CG; Klein, WW; Kristinsson, A; McGuire, DK; Newby, LK; Sadowski, Z; Shah, SH; Weaver, WD, 2005) |
"Both aspirin and beta-adrenergic blocking drugs have been shown to reduce the risk of death or acute myocardial infarction (AMI) in patients with unstable angina, but their effect during chronic use on the presentation of acute coronary syndromes is less well defined." | 2.69 | Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. ( Antman, EM; Becker, RC; Borzak, S; Braunwald, E; Cannon, CP; Douthat, L; Fuchs, J; Henry, T; Hochman, JS; Kraft, PL; McCabe, C; Palmeri, ST, 1998) |
"Tirofiban was generally well tolerated and, as compared with heparin, reduced ischemic events during the 48-hour infusion period, during which revascularization procedures were not performed." | 2.69 | A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. ( , 1998) |
"Eptifibatide was not associated with an increase in intracranial hemorrhage, and no significant effect on nonhemorrhagic stroke was observed." | 2.69 | Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. ( Alberts, MJ; Berdan, LG; Califf, RM; Deckers, J; Graffagnino, C; Granger, CB; Harrington, RA; Laskowitz, DT; Lincoff, AM; MacAulay, CM; Mahaffey, KW; Miller, JM; Simoons, ML; Sloan, MA; Topol, EJ, 1999) |
"Abciximab produced a 58% reduction in thrombus formation (11,631 +/- 861 vs 4, 925 +/- 585 microm(2); p <0." | 2.69 | Antithrombotic effects of abciximab. ( Badimon, JJ; Badimon, L; Chesebro, JH; Coller, BS; Dangas, G; Fallon, JT; Fuster, V; Hayes, R; Marmur, JD; Sharma, SK, 2000) |
"In dalteparin-treated patients, delta vWf was elevated (+48 +/- 8%) and did not differ from the unfractionated heparin group (NS)." | 2.69 | Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. ( Ankri, A; Choussat, R; Collet, JP; Drobinski, G; Lison, L; Montalescot, G; Perlemuter, K; Philippe, F; Thomas, D; Vicaut, E, 2000) |
"Unstable angina is associated with enhanced lipid peroxidation and reduced antioxidant defenses." | 2.69 | Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. ( Bucciarelli, T; Ciabattoni, G; Cipollone, F; Cuccurullo, F; Davì, G; Di Gregorio, D; Pasquale, M; Patrignani, P; Patrono, C, 2000) |
"When ticlopidine was given for 72 hours, TF levels were similar to normal laboratory values both in stable and unstable patients." | 2.69 | Effect of aspirin and ticlopidine on plasma tissue factor levels in stable and unstable angina pectoris. ( Ariëns, RA; Bernies, M; Bossi, IM; Brambilla, GM; Donatelli, F; Fajadet, J; Gregorini, L; Marco, I; Marco, J; Mari, D; Romano, SM; Somalvico, F, 2000) |
"Nonfatal myocardial infarction was present in seven patients in group A, four in group B and none in group C (group B vs." | 2.68 | Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. ( Cerdá, MA; Daroca, AM; Duronto, EA; García, CN; Gurfinkel, EP; Manos, EJ; Mautner, B; Mejaíl, RI, 1995) |
"Prognosis of unstable angina pectoris is related to admission EKG changes and prompt symptom control." | 2.68 | [Diltiazem versus intravenous nitroglycerin in the treatment of unstable angina pectoris. A randomized study]. ( Castro, P; Corbalán, R; Kunstmann, S; Vergara, I, 1995) |
"Dipyridamole was applied in 550 interventions (455 interventions in men, 95 interventions in women, age = 59." | 2.68 | [Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study]. ( Heidland, UE; Heintzen, MP; Kelm, M; Klimek, WJ; Leschke, M; Michel, CJ; Schwartzkopff, B; Strauer, BE; Vester, EG, 1997) |
"Ticlopidine was found to produce more marked effects on ADT-induced plasma platelet aggregation, in vivo reversible platelet aggregation, and reduced platelet levels of free cholesterol, as compared to aspirin." | 2.67 | [Ticlopidine and aspirin in the treatment of unstable angina: comparative evaluation of their effect of anti-aggregation and platelet membranes]. ( Mezhetskaia, IA; Shalaev, SV, 1993) |
"Heparin is an effective, widely used treatment for unstable angina." | 2.67 | Reactivation of unstable angina after the discontinuation of heparin. ( Juneau, M; Lam, J; McCans, J; Théroux, P; Waters, D, 1992) |
"We conclude that patients with unstable angina pectoris have a similar outcome after two years whether they receive medical therapy alone or coronary bypass surgery plus medical therapy." | 2.66 | Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study. ( Deupree, RH; Luchi, RJ; Scott, SM, 1987) |
"Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the clinical circumstances as discussed in this article." | 2.49 | Use of antiplatelet drugs in the treatment of acute coronary syndromes. ( Aronow, WS, 2013) |
"Non-ST elevation acute coronary syndromes are responsible for approximately 1 million admissions to U." | 2.48 | Unstable angina and non-ST elevation myocardial infarction. ( Braunwald, E, 2012) |
"As well as initiating thrombus formation at the site of a ruptured atherosclerotic plaque, platelets play a key role in vascular inflammation, through release of their own pro-inflammatory mediators and interactions with other relevant cell types (endothelial cells, leukocytes, and smooth muscle cells)." | 2.44 | Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. ( Badimon, JJ; Bhatt, DL; Herbert, JM; Lüscher, TF; Steinhubl, SR, 2007) |
"Elderly patients with unstable angina pectoris/non-ST-segment elevation myocardial infarction should be hospitalized." | 2.42 | Treatment of unstable angina pectoris/non-ST-segment elevation myocardial infarction in elderly patients. ( Aronow, WS, 2003) |
"Aspirin, however, has become a lifelong therapy for many patients, based on clinical trials and medical experience." | 2.42 | Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice. ( Kerr, JL; Oppelt, TF; Rowen, RC, 2004) |
"Patients presenting with unstable angina pectoris or non-Q-wave myocardial infarction (MI), if treated inadequately, are at a high risk of MI and subsequent mortality." | 2.41 | Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial. ( Adgey, AA; Manoharan, G, 2002) |
"The National Heart Attack Alert Program established a Working Group to review the utility of critical pathways on quality of care and outcomes for patients with ACS." | 2.41 | Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. ( Bahr, R; Boden, WE; Cannon, CP; Christenson, R; Eagle, K; Gibler, WB; Hand, MH; Lambrew, CT; Lee, TH; MacLeod, B; Ornato, JP; Selker, HP; Steele, P; Zalenski, RJ, 2002) |
" Because of the need for frequent anticoagulation monitoring and dosage adjustment, the use of heparin is limited to short-term treatment during the acute in-hospital phase." | 2.40 | New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials. ( Cohen, M, 1998) |
" Clinical trial evidence is now available to show that the LMWH enoxaparin, in a dosage of 1." | 2.40 | Treatment options in unstable angina: a clinical update. ( Antman, EM; Fox, KA, 1998) |
" Women presenting with unstable angina or myocardial infarction should receive aspirin 325 mg as soon as the diagnosis is confirmed, and this dosage should be continued on a chronic basis." | 2.38 | Aspirin for the prevention of vascular death in women. ( Corn, CR; Hamilton, SF; McAnally, LE, 1992) |
"Unstable angina is a clinical syndrome characterized by increased rate and severity of angina pectoris attacks and, sometimes but not always, accompanied by ECG changes similar to those seen in coronary insufficiency." | 2.38 | Unstable angina: pathophysiology and drug therapy. ( Bleifeld, W, 1990) |
" There was disagreement concerning the dosage of heparin and the exact use of betablockers, aspirin, warfarin, ACE-inhibitors, magnesium and antiarrhythmics." | 2.38 | [Drug therapy of acute coronary syndrome. Summary of a hearing arranged by the Norwegian Cardiologic Society and the Institute of pharmacotherapy]. ( Amlie, JP; Aursnes, I; Osnes, JB; Platou, ES; Smiseth, OA, 1990) |
"In secondary-prevention trials to treat unstable angina, which were performed in USA and Canada, the number of non-fatal myocardial infarctions was reduced by about 50 per cent." | 2.38 | Anti-thrombotic drugs in the treatment of coronary heart disease: the present situation with aspirin. ( Born, GV, 1990) |
"Heparin therapy for unstable angina has appeared promising, but no properly conducted randomized trial has been accomplished." | 2.37 | Which role for antiplatelet and anticoagulant drugs in unstable angina pectoris? ( Lewis, HD, 1988) |
"Age above 55 years was associated with recurrence of ACS in C2238/ANP-minor allele carriers (hazard ratio 1." | 1.43 | T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients. ( Abbolito, S; Battistoni, A; Bianchi, F; Burocchi, S; Cangianiello, S; Caprinozzi, M; Comito, F; Cotugno, M; De Giusti, M; Di Castro, S; Dito, E; Farcomeni, A; Greco, ES; Marchitti, S; Pagliaro, B; Pierelli, G; Rubattu, S; Sciarretta, S; Stanzione, R; Volpe, M, 2016) |
"Aspirin fills were more common in younger veterans, Blacks, Hispanics, males, hypertensive veterans, mentally ill patients, those with no co-pay and those prescribed antiplatelets/anticoagulants in addition to aspirin postoperatively." | 1.42 | Use of Health Care System-Supplied Aspirin by Veterans With Postoperative Heart Attack or Unstable Angina. ( Copeland, LA; MacCarthy, DJ; McNeal, CJ; Mortensen, EM; Pugh, MJ; Rivera, CM, 2015) |
"Smoking, alcohol abuse, and obesity were more common in patients with ST elevation myocardial infarction (STEMI) (P < 0." | 1.42 | Management of acute coronary syndromes in a developing country; time for a paradigm shift? an observational study. ( Bandara, R; De Silva, C; Galgomuwa, MP; Medagama, A, 2015) |
"Hemorrhagic cholecystitis is a rare and potentially fatal complication of biliary tract disease." | 1.36 | Hemorrhagic cholecystitis after anticoagulation therapy. ( Chen, CL; Chen, YY; Hsu, YH; Huang, SC; Yi, CH, 2010) |
"Aspirin resistance was observed in 38 patients (36." | 1.35 | Responsiveness to aspirin in patients with unstable angina pectoris by whole blood aggregometry. ( Dong, HM; Huang, L; Jian, Z; Li, JB; Wu, XJ; Yu, SY; Zhao, XH, 2009) |
" Examined a different way, the mean percentage of days that the correct aspirin dosage (1 pill per day for all patients) was taken was significantly lower in the persistently depressed patients (76." | 1.33 | Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes. ( Burg, MM; Chaplin, WF; Davidson, KW; Gerin, W; Haas, D; Kronish, IM; Rieckmann, N; Vorchheimer, D, 2006) |
"Diabetes Mellitus is a chronic disease frequently associated to ischemic heart disease and both disease require continuing medical care, aggressive treatment of other risk factors, educational programs for self management of disease to prevent acute complication." | 1.32 | [Recommendations for cardiovascular rehabilitation in diabetes mellitus]. ( Biorci, ML; Camerini, A; Chieffo, C; Comaschi, M; Faglia, E; Fattirolli, F; Gattone, M; Giorda, C; Griffo, R; Mannucci, E, 2003) |
"In patients with unstable angina pectoris or non-ST-elevation myocardial infarction treated with aspirin, heparin, and tirofiban, performance of an exercise or a pharmacologic stress test in selected patients within 48 to 72 hours after admission appears to be associated with a low risk of complications." | 1.32 | Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction. ( Cannon, CP; Dibattiste, PM; Gibson, CM; Karha, J; Murphy, SA, 2004) |
"Unstable angina was defined as transient S-T segment changes without significant increases in CK and CK-MB." | 1.31 | Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils. ( de Andres, R; Farré, J; García-Méndez, A; Gómez, J; López-Farré, A; Mateos-Cáreres, PJ; Rico, L; Romero, J; Sánchez de Miguel, L, 2002) |
"Aspirin has the potential to influence CRP release, either by its anti-inflammatory activity or by reducing myocardial necrosis." | 1.31 | The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. ( Clarke, H; Cooper, J; Kennon, S; Mills, PG; Price, CP; Ranjadayalan, K; Timmis, AD, 2001) |
" We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk." | 1.31 | Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. ( Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS, 2001) |
"Aspirin was prescribed to 82." | 1.31 | Quality of care among elderly patients hospitalized with unstable angina. ( Krumholz, HM; Lewis, JM; Petrillo, MK; Radford, MJ; Rathore, SS; Shahi, CN; Thakur, R; Wang, Y; Wu, WC, 2001) |
" The investigations were performed with different amounts of 4 different inducers (ADP, arachidonic acid, epinephrine and collagen) taking dose-response curves." | 1.30 | [The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis]. ( Barczi, V; Blaskó, G; Dinnyés, J; Hamvas, J; Jáger, R; Kinczel, A; Pál, A; Poór, F; Salamon, A; Tarján, J, 1999) |
" With the increase of aspirin dosage the degree of these two changes increased (P < 0." | 1.29 | [Effects of different lowdoses of aspirin on platelet activation and the number of platelets in the patients with coronary heart disease]. ( Ouyang, M; Sheng, C; Si, F, 1996) |
"Questionnaires about therapy in unstable angina pectoris were sent to 63 Danish medical departments and were answered by 52 departments (82." | 1.28 | [Treatment of unstable angina pectoris. A questionnaire study]. ( Christiansen, IB; Juul, A; Nielsen, JD; Siemsen, M; Stoltenberg, M, 1990) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 44 (8.84) | 18.7374 |
1990's | 183 (36.75) | 18.2507 |
2000's | 227 (45.58) | 29.6817 |
2010's | 38 (7.63) | 24.3611 |
2020's | 6 (1.20) | 2.80 |
Authors | Studies |
---|---|
Marquis-Gravel, G | 1 |
Robert-Halabi, M | 1 |
Bainey, KR | 1 |
Tanguay, JF | 1 |
Mehta, SR | 8 |
Martí, D | 1 |
Carballeira, D | 1 |
Morales, MJ | 1 |
Concepción, R | 1 |
Del Castillo, H | 1 |
Marschall, A | 1 |
Delgado-Calva, FA | 1 |
Dejuán-Bitriá, C | 1 |
Pérez-Guzmán, J | 1 |
López-Soberón, E | 1 |
Palazuelos, J | 2 |
Álvarez-Antón, S | 1 |
Cheng, D | 1 |
Zhao, S | 1 |
Hao, Y | 1 |
Corbett, SJ | 1 |
Ftouh, S | 1 |
Lewis, S | 1 |
Lovibond, K | 1 |
Clarkson, SA | 1 |
Heindl, B | 1 |
Cai, A | 1 |
Beasley, M | 1 |
Dillon, C | 1 |
Limdi, N | 1 |
Brown, TM | 1 |
Wang, W | 1 |
Wang, X | 1 |
Zhang, L | 2 |
Zhang, J | 1 |
Man, F | 1 |
Pan, Q | 1 |
Guo, L | 1 |
Bishop, W | 1 |
Girao, G | 1 |
Schäfer, A | 3 |
Bauersachs, J | 2 |
Ertaş, FS | 1 |
Tokgozoglu, L | 1 |
Aronow, WS | 2 |
Arntz, HR | 1 |
Boudriot, E | 1 |
Garlichs, C | 1 |
Hoffmann, S | 1 |
Ince, H | 1 |
Klingenheben, T | 1 |
Weil, J | 1 |
Zugck, C | 1 |
Helms, TM | 1 |
Silber, S | 1 |
Zaval's'ka, TV | 1 |
Cho, EH | 1 |
Ligh, C | 1 |
Hodulik, KL | 1 |
Hollenbeck, ST | 1 |
Agmadova, ZM | 1 |
Kallaeva, AN | 1 |
Rubattu, S | 1 |
De Giusti, M | 1 |
Farcomeni, A | 1 |
Abbolito, S | 1 |
Comito, F | 1 |
Cangianiello, S | 1 |
Greco, ES | 1 |
Dito, E | 1 |
Pagliaro, B | 1 |
Cotugno, M | 1 |
Stanzione, R | 1 |
Marchitti, S | 1 |
Bianchi, F | 1 |
Di Castro, S | 1 |
Battistoni, A | 1 |
Burocchi, S | 1 |
Caprinozzi, M | 1 |
Pierelli, G | 1 |
Sciarretta, S | 1 |
Volpe, M | 1 |
Rajpurohit, N | 1 |
Ayaz, SZ | 1 |
Yee, J | 1 |
Khan, MA | 1 |
Stys, A | 1 |
Barbieri, L | 1 |
Verdoia, M | 1 |
Schaffer, A | 1 |
Marino, P | 1 |
De Luca, G | 1 |
Rivera, CM | 1 |
Copeland, LA | 1 |
McNeal, CJ | 1 |
Mortensen, EM | 1 |
Pugh, MJ | 1 |
MacCarthy, DJ | 1 |
Medagama, A | 1 |
Bandara, R | 1 |
De Silva, C | 1 |
Galgomuwa, MP | 1 |
Beauloye, C | 1 |
Vrolix, M | 1 |
Claeys, MJ | 1 |
van de Borne, P | 1 |
Vandendriessche, E | 1 |
Van De Werf, F | 4 |
Hagström, E | 1 |
Roe, MT | 6 |
Hafley, G | 1 |
Neely, ML | 1 |
Sidhu, MS | 1 |
Winters, KJ | 2 |
Prabhakaran, D | 4 |
White, HD | 10 |
Armstrong, PW | 10 |
Fox, KA | 15 |
Ohman, EM | 7 |
Boden, WE | 3 |
Buccheri, D | 1 |
Minacapelli, A | 1 |
Piraino, D | 1 |
La Grutta, L | 1 |
Andolina, G | 1 |
Cornel, JH | 5 |
Neely, B | 2 |
Jakubowski, JA | 2 |
Bhatt, DL | 7 |
Ardissino, D | 3 |
Erlinge, D | 2 |
Tantry, US | 2 |
Gurbel, PA | 3 |
Yan, FF | 3 |
Liu, YF | 3 |
Liu, Y | 3 |
Zhao, YX | 3 |
Moliterno, DJ | 6 |
Li, JB | 1 |
Dong, HM | 1 |
Jian, Z | 1 |
Wu, XJ | 1 |
Zhao, XH | 1 |
Yu, SY | 1 |
Huang, L | 1 |
Wang, TY | 1 |
Ou, FS | 1 |
Harrington, RA | 7 |
Gibler, WB | 3 |
Peterson, ED | 2 |
Guerra, M | 1 |
Mota, JC | 1 |
Veloso, M | 1 |
Gama, V | 1 |
Vouga, L | 1 |
Sarkees, ML | 1 |
Bavry, AA | 1 |
Acikel, S | 1 |
Yildirir, A | 1 |
Aydinalp, A | 1 |
Bal, U | 1 |
Kaynar, G | 1 |
Ozin, B | 1 |
Muderrisoglu, H | 1 |
Unger, EF | 1 |
Venkitachalam, L | 1 |
Kip, KE | 1 |
Mulukutla, SR | 1 |
Selzer, F | 1 |
Laskey, W | 1 |
Slater, J | 1 |
Cohen, HA | 1 |
Wilensky, RL | 2 |
Williams, DO | 3 |
Marroquin, OC | 1 |
Sutton-Tyrrell, K | 1 |
Bunker, CH | 1 |
Kelsey, SF | 1 |
Damman, P | 1 |
Hirsch, A | 2 |
Windhausen, F | 2 |
Tijssen, JG | 2 |
de Winter, RJ | 2 |
Zafar, MU | 1 |
Paz-Yepes, M | 1 |
Shimbo, D | 1 |
Vilahur, G | 1 |
Burg, MM | 2 |
Chaplin, W | 1 |
Fuster, V | 6 |
Davidson, KW | 2 |
Badimon, JJ | 4 |
Kojuri, J | 1 |
Mahmoody, Y | 1 |
Zangbar Sabegh, B | 1 |
Jannati, M | 1 |
Mahboodi, A | 1 |
Khalili, A | 1 |
Chen, YY | 1 |
Yi, CH | 1 |
Chen, CL | 1 |
Huang, SC | 1 |
Hsu, YH | 1 |
Zeymer, U | 1 |
Zahn, R | 2 |
Senges, J | 1 |
Gitt, A | 1 |
Ortega-Loayza, AG | 1 |
Raza, S | 1 |
Minisi, AJ | 1 |
Topaz, O | 1 |
Heller, A | 1 |
Jovin, IS | 1 |
Husted, SE | 3 |
Nielsen, HK | 1 |
Merella, P | 1 |
Casu, G | 1 |
Meloni, I | 1 |
Good, CW | 1 |
Berger, PB | 3 |
Radke, PW | 1 |
Alexander, JH | 2 |
Lopes, RD | 1 |
James, S | 1 |
Kilaru, R | 1 |
He, Y | 1 |
Mohan, P | 1 |
Goodman, S | 2 |
Verheugt, FW | 7 |
Flather, M | 2 |
Huber, K | 5 |
Liaw, D | 1 |
Lopez-Sendon, J | 2 |
De Caterina, R | 3 |
Jansky, P | 1 |
Darius, H | 3 |
Vinereanu, D | 1 |
Cools, F | 1 |
Atar, D | 1 |
Leiva-Pons, JL | 2 |
Keltai, M | 1 |
Ogawa, H | 5 |
Pais, P | 1 |
Parkhomenko, A | 2 |
Ruzyllo, W | 3 |
Diaz, R | 2 |
White, H | 2 |
Ruda, M | 1 |
Geraldes, M | 1 |
Lawrence, J | 1 |
Wallentin, L | 11 |
Hoshida, S | 1 |
Yuasa, F | 1 |
Lim, YJ | 1 |
Kijima, Y | 1 |
Iwasaka, J | 1 |
Iwasaka, T | 1 |
Braunwald, E | 8 |
Vassilev, D | 1 |
Hazan, M | 1 |
Dean, L | 1 |
Jia, XQ | 1 |
Dong, CM | 1 |
Qin, J | 1 |
Kourlaba, G | 1 |
Fragoulakis, V | 1 |
Maniadakis, N | 1 |
Kilickesmez, KO | 1 |
Kocas, C | 1 |
Abaci, O | 1 |
Okcun, B | 1 |
Gorcin, B | 1 |
Gurmen, T | 1 |
May, CH | 1 |
Lincoff, AM | 4 |
Goodman, SG | 5 |
Clemmensen, P | 1 |
Martinez, F | 1 |
Nicolau, JC | 3 |
Dalby, AJ | 1 |
McGuire, DK | 4 |
Gottlieb, S | 1 |
Topacio, GO | 1 |
Hamm, C | 1 |
Pavlides, G | 1 |
Goudev, AR | 1 |
Oto, A | 1 |
Tseng, CD | 1 |
Merkely, B | 1 |
Gasparovic, V | 1 |
Corbalan, R | 2 |
Cinteză, M | 1 |
McLendon, RC | 1 |
Brown, EB | 1 |
Lokhnygina, Y | 2 |
Aylward, PE | 4 |
Hochman, JS | 5 |
Neely, M | 1 |
Chan, MY | 1 |
Brown, E | 1 |
Zhou, C | 1 |
Klein, W | 4 |
Brieger, D | 1 |
Steg, PG | 2 |
Dabbous, O | 1 |
Avezum, A | 1 |
Natarajan, M | 5 |
Loma-Osorio, A | 1 |
García-Castrillo, L | 1 |
Arós, F | 1 |
Lopetegui, P | 1 |
Recuerda, E | 1 |
Epelde, F | 1 |
Alberts, MJ | 2 |
Easton, JD | 1 |
McRedmond, J | 1 |
Fitzgerald, D | 1 |
Orford, JL | 2 |
Lennon, R | 1 |
Melby, S | 2 |
Fasseas, P | 2 |
Bell, MR | 1 |
Rihal, CS | 1 |
Holmes, DR | 5 |
Howard, PA | 1 |
Grenier, O | 2 |
Cambou, JP | 2 |
Ferrières, J | 2 |
Thomas, D | 3 |
Amelineau, E | 2 |
Cantet, C | 2 |
Danchin, N | 3 |
Niiazova-Karben, ZA | 1 |
Sidorenko, BA | 1 |
Batyraliev, TA | 1 |
Preobrazhenskiĭ, DV | 1 |
Pershukov, IV | 1 |
Pia, IuV | 1 |
Daniiarov, BS | 1 |
Theroux, P | 9 |
Cipollone, F | 3 |
Ganci, A | 1 |
Greco, A | 2 |
Panara, MR | 2 |
Pasquale, M | 2 |
Di Gregorio, D | 2 |
Porreca, E | 1 |
Mezzetti, A | 1 |
Cuccurullo, F | 3 |
Patrignani, P | 4 |
Mateos-Cáreres, PJ | 1 |
García-Méndez, A | 1 |
Farré, J | 1 |
Sánchez de Miguel, L | 1 |
Gómez, J | 1 |
de Andres, R | 1 |
Rico, L | 1 |
Romero, J | 1 |
López-Farré, A | 1 |
Grand, A | 1 |
Moustapha, A | 1 |
Anderson, HV | 2 |
Collet, JP | 2 |
Montalescot, G | 3 |
Fine, E | 1 |
Golmard, JL | 1 |
Dalby, M | 1 |
Choussat, R | 2 |
Ankri, A | 2 |
Dumaine, R | 1 |
Lesty, C | 1 |
Vignolles, N | 1 |
Hughes, K | 1 |
Yusuf, S | 8 |
Zhao, F | 3 |
Gersh, BJ | 2 |
Commerford, PJ | 2 |
Blumenthal, M | 1 |
Budaj, A | 1 |
Wittlinger, T | 1 |
Gille, J | 1 |
Bernotat, J | 1 |
Böhm, S | 1 |
Behrens, P | 1 |
Löhr, JF | 1 |
Gharbi, M | 1 |
Barakett, N | 1 |
Lahidheb, DH | 1 |
Smiri, Z | 1 |
Fehri, W | 1 |
Azzouzi, F | 1 |
Rahal, N | 1 |
Mhenni, H | 1 |
Haouala, H | 1 |
Guediche, M | 1 |
Gerschutz, GP | 1 |
Hanania, G | 1 |
Vaur, L | 1 |
Guéret, P | 1 |
Blanchard, D | 1 |
Genès, N | 1 |
Lablanche, JM | 1 |
Maurin, T | 1 |
Zeller, M | 1 |
Cottin, Y | 1 |
Touzery, C | 1 |
Beer, JC | 1 |
L'Huillier, I | 1 |
Fraison, M | 1 |
Buffet, P | 1 |
Louis, P | 1 |
Wolf, JE | 1 |
Damås, JK | 2 |
Waehre, T | 2 |
Yndestad, A | 2 |
Otterdal, K | 2 |
Hognestad, A | 1 |
Solum, NO | 1 |
Gullestad, L | 2 |
Frøland, SS | 2 |
Aukrust, P | 2 |
Biviano, AB | 1 |
Rabbani, LE | 1 |
Paultre, F | 1 |
Hurley, E | 1 |
Sullivan, J | 1 |
Giglio, J | 1 |
Mosca, L | 1 |
Fries, R | 1 |
Böhm, M | 1 |
Kopp, CW | 1 |
Steiner, S | 1 |
Priglinger, U | 1 |
Christ, G | 1 |
Probst, P | 1 |
Maurer, G | 1 |
Minar, E | 1 |
Okmen, E | 1 |
Cakmak, M | 1 |
Tartan, Z | 1 |
Cam, N | 1 |
Kennon, S | 2 |
Price, CP | 2 |
Mills, PG | 2 |
Macey, M | 1 |
Cooper, J | 2 |
Clarke, H | 2 |
Timmis, AD | 2 |
Peters, RJ | 1 |
Lewis, BS | 1 |
Kopecky, SL | 1 |
Valentin, V | 2 |
Wodlinger, AM | 1 |
Pieper, JA | 1 |
Averkov, OV | 3 |
Slavina, NN | 1 |
Gratsianskiĭ, NA | 4 |
Srichai, MB | 1 |
Jaber, WA | 1 |
Prior, DL | 1 |
Marso, SP | 1 |
Houghtaling, PL | 1 |
Menon, V | 1 |
Simoons, ML | 7 |
Lange, RA | 1 |
Hillis, LD | 3 |
Manoharan, G | 1 |
Adgey, AA | 1 |
Teal, PA | 1 |
Sabatine, MS | 1 |
Morrow, DA | 1 |
Giugliano, RP | 2 |
Murphy, SA | 4 |
Demopoulos, LA | 2 |
DiBattiste, PM | 3 |
Weintraub, WS | 4 |
McCabe, CH | 5 |
Antman, EM | 7 |
Cannon, CP | 12 |
Faraday, N | 1 |
Braunstein, JB | 1 |
Heldman, AW | 1 |
Bolton, ED | 1 |
Chiles, KA | 1 |
Gerstenblith, G | 3 |
Schulman, SP | 5 |
Burger, K | 1 |
Steinhubl, SR | 4 |
Kimura, K | 1 |
Kosuge, M | 1 |
Rodgers, JE | 1 |
Camerini, A | 1 |
Chieffo, C | 1 |
Griffo, R | 1 |
Comaschi, M | 1 |
Gattone, M | 1 |
Mannucci, E | 1 |
Faglia, E | 1 |
Giorda, C | 1 |
Biorci, ML | 1 |
Fattirolli, F | 1 |
Arjomand, H | 1 |
Cohen, M | 9 |
Ezekowitz, MD | 1 |
Bakhritdinov, FSh | 1 |
Kamilov, ShM | 1 |
Trynkin, AV | 1 |
Babadzhanov, SA | 1 |
Kandzari, DE | 1 |
Banas, JS | 1 |
Gawaz, M | 1 |
Müller, I | 1 |
Besta, F | 1 |
Aghababian, RV | 1 |
Peters, R | 1 |
Lakkis, N | 2 |
Kerr, JL | 1 |
Oppelt, TF | 1 |
Rowen, RC | 1 |
Kassem-Moussa, H | 1 |
Mahaffey, KW | 2 |
Graffagnino, C | 2 |
Tasissa, G | 1 |
Sila, CA | 1 |
Simes, RJ | 1 |
Califf, RM | 11 |
Bhapkar, MV | 3 |
Newby, LK | 8 |
Rupprecht, HJ | 2 |
Hirsh, J | 4 |
Melero, JM | 1 |
Porras, C | 1 |
Such, M | 1 |
Olalla, E | 1 |
Alonso, J | 1 |
Stejskal, D | 1 |
Prosková, J | 1 |
Lacnák, B | 1 |
Horalík, D | 1 |
Hamplová, A | 1 |
Oral, I | 1 |
Hrabovská, I | 1 |
Ochmanová, R | 1 |
Adamovská, S | 1 |
Juráková, R | 1 |
Ozanová, G | 1 |
Juchelka, J | 1 |
Kulísková, O | 1 |
Pĕnkavová, H | 1 |
Michelson, AD | 1 |
Chesebro, JH | 7 |
Karha, J | 1 |
Gibson, CM | 3 |
Sonson, JM | 1 |
Lum, JJ | 1 |
Madison, JR | 1 |
Seto, TB | 1 |
Spies, C | 1 |
Kumana, CR | 1 |
Cheung, G | 1 |
Lauder, IJ | 1 |
Cheung, BM | 1 |
Campbell, CL | 1 |
Schleinitz, MD | 1 |
Heidenreich, PA | 1 |
Lim, MJ | 1 |
Spencer, FA | 2 |
Gore, JM | 2 |
Dabbous, OH | 2 |
Agnelli, G | 2 |
Kline-Rogers, EM | 1 |
Dibenedetto, D | 1 |
Eagle, KA | 2 |
Mehta, RH | 2 |
Pettersen, AA | 1 |
Seljeflot, I | 1 |
Abdelnoor, M | 1 |
Arnesen, H | 1 |
Aranki, S | 1 |
Byrne, J | 1 |
Bhatia, D | 1 |
Mehta, S | 1 |
Mills, R | 1 |
Elsässer, A | 1 |
Nef, H | 1 |
Möllmann, H | 1 |
Hamm, CW | 1 |
Akowuah, E | 1 |
Shrivastava, V | 1 |
Jamnadas, B | 1 |
Hopkinson, D | 1 |
Sarkar, P | 1 |
Storey, R | 1 |
Braidley, P | 1 |
Cooper, G | 1 |
James, SK | 1 |
Oldgren, J | 1 |
Lindbäck, J | 1 |
Johnston, N | 1 |
Siegbahn, A | 1 |
Sick, PB | 1 |
Brosteanu, O | 1 |
Ulrich, M | 1 |
Thiele, H | 1 |
Niebauer, J | 1 |
Busch, I | 1 |
Schuler, G | 1 |
Granger, CB | 4 |
Peterson, E | 1 |
Kline-Rogers, E | 1 |
Allegrone, J | 1 |
Dibra, A | 1 |
Mehilli, J | 1 |
Braun, S | 1 |
Hadamitzky, M | 1 |
Baum, H | 1 |
Dirschinger, J | 1 |
Schühlen, H | 1 |
Schömig, A | 1 |
Kastrati, A | 1 |
Trappe, HJ | 1 |
Perings, C | 1 |
Andreotti, F | 1 |
Testa, L | 1 |
Biondi-Zoccai, GG | 1 |
Crea, F | 1 |
Eriksson, P | 1 |
Rothberg, M | 1 |
Douglas, JS | 1 |
Kereiakes, DJ | 2 |
Grines, CL | 1 |
Block, E | 1 |
Ghazzal, ZM | 1 |
Morris, DC | 1 |
Liberman, H | 1 |
Parker, K | 1 |
Jurkovitz, C | 1 |
Murrah, N | 1 |
Foster, J | 1 |
Hyde, P | 1 |
Mancini, GB | 2 |
Keough-Ryan, TM | 1 |
Kiberd, BA | 1 |
Dipchand, CS | 1 |
Cox, JL | 1 |
Rose, CL | 1 |
Thompson, KJ | 1 |
Clase, CM | 1 |
Harrison, P | 1 |
Mackie, I | 1 |
Mathur, A | 1 |
Robinson, MS | 1 |
Hong, Y | 1 |
Erusalimsky, JD | 1 |
Machin, SJ | 1 |
Martin, JF | 3 |
Frazier, CG | 1 |
Shah, SH | 1 |
Sadowski, Z | 1 |
Kristinsson, A | 2 |
Klein, WW | 2 |
Weaver, WD | 2 |
Gidwani, S | 1 |
Body, R | 1 |
Smith, EE | 1 |
Murphy, S | 2 |
Feske, SK | 1 |
Schwamm, LH | 1 |
Fitchett, DH | 1 |
Langer, A | 2 |
Tan, M | 1 |
Mendelsohn, A | 1 |
Chen, YG | 1 |
Xu, F | 1 |
Zhang, Y | 3 |
Ji, QS | 1 |
Sun, Y | 1 |
Lü, RJ | 1 |
Li, RJ | 1 |
Bierbach, B | 1 |
Horstick, G | 1 |
Berg, O | 1 |
Heimann, A | 1 |
Münzel, T | 1 |
Vahl, CF | 1 |
Kempski, O | 1 |
Asaro, PV | 1 |
Sheldahl, AL | 1 |
Char, DM | 1 |
Casella, G | 1 |
Greco, C | 1 |
Maggioni, AP | 1 |
Di Pasquale, G | 1 |
Ikeda, U | 1 |
Shimamoto, K | 1 |
Kawana, M | 1 |
Umman, B | 2 |
Vavuranakis, M | 1 |
Latsios, G | 1 |
Aggelis, D | 1 |
Bosinakou, I | 1 |
Karambelas, I | 1 |
Tousoulis, D | 1 |
Toutouzas, K | 1 |
Stefanadis, C | 1 |
Graff, LG | 1 |
Wang, Y | 4 |
Borkowski, B | 1 |
Tuozzo, K | 1 |
Foody, JM | 1 |
Krumholz, HM | 4 |
Radford, MJ | 3 |
Mannini, L | 1 |
Marcucci, R | 1 |
Paniccia, R | 1 |
Antonucci, E | 1 |
Giglioli, C | 1 |
Valente, S | 1 |
Gori, AM | 2 |
Prisco, D | 2 |
Gensini, GF | 5 |
Abbate, R | 2 |
Scirica, BM | 1 |
Cooper, R | 1 |
Aster, RH | 1 |
Brassard, J | 1 |
Charlesworth, A | 1 |
Skene, AM | 1 |
Pamukcu, B | 1 |
Oflaz, H | 1 |
Oncul, A | 1 |
Mercanoglu, F | 1 |
Ozcan, M | 1 |
Meric, M | 1 |
Nisanci, Y | 1 |
Kjaer, J | 1 |
Larsen, CH | 1 |
Poulsen, TS | 1 |
Møller, JE | 1 |
Mickley, H | 1 |
Smith, C | 1 |
Øie, E | 1 |
Sandberg, WJ | 1 |
Scholz, H | 1 |
Endresen, K | 1 |
Olofsson, PS | 1 |
Halvorsen, B | 1 |
Hansson, GK | 1 |
Rieckmann, N | 1 |
Kronish, IM | 1 |
Haas, D | 1 |
Gerin, W | 1 |
Chaplin, WF | 1 |
Vorchheimer, D | 1 |
Stone, GW | 2 |
Decker, C | 1 |
Huddleston, J | 1 |
Kosiborod, M | 1 |
Buchanan, DM | 1 |
Stoner, C | 1 |
Jones, A | 1 |
Banerjee, S | 1 |
Spertus, JA | 1 |
Weisz, G | 1 |
Moses, JW | 2 |
Teirstein, PS | 2 |
Raizner, AE | 1 |
Satler, LF | 1 |
Mishkel, G | 1 |
Wang, P | 1 |
Kuntz, RE | 1 |
Popma, JJ | 2 |
Leon, MB | 1 |
Yu, HM | 2 |
Zhang, C | 2 |
Yang, RX | 2 |
Tickoo, S | 1 |
Milford-Beland, S | 1 |
Pollack, CV | 1 |
Herbert, JM | 1 |
Lüscher, TF | 1 |
Wong, CK | 2 |
Bhapker, MV | 1 |
Pfisterer, M | 1 |
Alexander, KP | 1 |
San Miguel Hernández, A | 1 |
Inglada-Galiana, L | 1 |
García Iglesias, R | 1 |
Alonso Castillejos, N | 1 |
Martín Gil, FJ | 1 |
Matsukawa, M | 1 |
Kaikita, K | 1 |
Soejima, K | 1 |
Fuchigami, S | 1 |
Nakamura, Y | 1 |
Honda, T | 1 |
Tsujita, K | 1 |
Nagayoshi, Y | 1 |
Kojima, S | 1 |
Shimomura, H | 1 |
Sugiyama, S | 1 |
Fujimoto, K | 1 |
Yoshimura, M | 2 |
Nakagaki, T | 1 |
Greenbaum, AB | 1 |
Pieper, KS | 1 |
Ferguson, JJ | 4 |
Wilson, JM | 2 |
Diez, J | 1 |
Richard Conti, C | 1 |
Angiolillo, DJ | 1 |
Bernardo, E | 1 |
Sabaté, M | 1 |
Jimenez-Quevedo, P | 1 |
Costa, MA | 1 |
Hernández-Antolin, R | 1 |
Moreno, R | 1 |
Escaned, J | 1 |
Alfonso, F | 1 |
Bañuelos, C | 1 |
Guzman, LA | 1 |
Bass, TA | 1 |
Macaya, C | 2 |
Fernandez-Ortiz, A | 1 |
Simon, DI | 1 |
Schmaier, AH | 1 |
Sarembock, IJ | 1 |
Krucoff, MW | 1 |
O'Neill, WW | 1 |
Waksman, R | 1 |
Buchbinder, M | 1 |
Mehran, R | 1 |
Meredith, IT | 1 |
Ibuki, C | 1 |
Kolm, P | 1 |
Yuan, Y | 1 |
Veledar, E | 1 |
O'Brien, JA | 1 |
Walker, CW | 1 |
Dawley, CA | 1 |
Fletcher, SF | 1 |
Sechtem, U | 1 |
Kirichenko, AA | 1 |
Mantserova, OA | 1 |
Lebedeva, AIu | 1 |
D'iachkova, NV | 1 |
Voloshina, NM | 1 |
Mazurov, VI | 1 |
Nifontov, VM | 1 |
Tyrenko, VV | 1 |
Kolina, IG | 1 |
Cherkashina, AL | 1 |
Shkodina, NV | 1 |
Mazalov, KV | 1 |
Spiropulos, NA | 1 |
Eremenko, IA | 1 |
Kuzin, AI | 1 |
FitzGerald, GA | 2 |
Zhao, Y | 1 |
Shen, LH | 1 |
Yang, M | 1 |
Nielsen, AA | 1 |
Veien, KT | 1 |
Jørgensen, LG | 1 |
Buck, TC | 1 |
Brandslund, I | 1 |
Christensen, C | 1 |
Mikkelsson, J | 1 |
Eskola, M | 1 |
Nikus, K | 1 |
Karhunen, PJ | 1 |
Niemela, K | 1 |
Varas-Lorenzo, C | 1 |
Castellsague, J | 1 |
Stang, MR | 1 |
Tomas, L | 1 |
Aguado, J | 1 |
Perez-Gutthann, S | 1 |
Wiviott, SD | 1 |
Voitk, J | 1 |
Hasin, Y | 1 |
Widimsky, P | 2 |
Chandna, H | 1 |
Macias, W | 1 |
Lewis, HD | 4 |
Davis, JW | 1 |
Archibald, DG | 1 |
Steinke, WE | 1 |
Smitherman, TC | 1 |
Doherty, JE | 1 |
Schnaper, HW | 1 |
LeWinter, MM | 1 |
Linares, E | 1 |
Pouget, JM | 1 |
Sabharwal, SC | 1 |
Chesler, E | 1 |
DeMots, H | 1 |
Epstein, SE | 1 |
Palmeri, ST | 2 |
Hayashi, H | 1 |
Kisamori, K | 1 |
Kaneko, M | 1 |
Masumura, Y | 1 |
Kamikawa, T | 1 |
Kobayashi, A | 1 |
Suzuki, Y | 1 |
Yamazaki, N | 1 |
Yamaguchi, T | 2 |
Harada, Y | 1 |
Willerson, JT | 3 |
Campbell, WB | 1 |
Winniford, MD | 1 |
Schmitz, J | 1 |
Apprill, P | 1 |
Firth, BG | 1 |
Ashton, J | 1 |
Smitherman, T | 1 |
Bush, L | 1 |
Buja, LM | 2 |
Deckers, JW | 3 |
Larsson, H | 3 |
Areskog, M | 3 |
Areskog, NH | 3 |
Jonasson, T | 2 |
Ringqvist, I | 2 |
Fellenius, C | 2 |
Strickland, C | 1 |
Newton, W | 1 |
Gurfinkel, EP | 4 |
Manos, EJ | 1 |
Mejaíl, RI | 1 |
Cerdá, MA | 1 |
Duronto, EA | 1 |
García, CN | 1 |
Daroca, AM | 1 |
Mautner, B | 2 |
Jenkins, DP | 1 |
Sumeray, M | 1 |
Montgomery, HE | 1 |
Chester, MR | 1 |
Fuchs, J | 2 |
Garcia-Dorado, D | 2 |
Tornos, P | 1 |
Sambola, A | 1 |
Oliveras, J | 2 |
Santos, M | 1 |
Soler Soler, J | 1 |
Modesti, PA | 4 |
Colella, A | 1 |
Cecioni, I | 1 |
Costoli, A | 1 |
Biagini, D | 1 |
Migliorini, A | 1 |
Neri Serneri, GG | 5 |
Branzi, A | 1 |
Melandri, G | 1 |
Poggesi, L | 3 |
Rostagno, C | 2 |
Tamburini, C | 1 |
Carnovali, M | 1 |
Magnani, B | 1 |
Shorten, G | 1 |
Comunale, ME | 1 |
Johnson, RG | 1 |
Bodó, I | 1 |
Németh, C | 1 |
Littmann, L | 1 |
McMurray, J | 1 |
Rankin, A | 1 |
Sámóczi, M | 1 |
Farkas, A | 1 |
Sipos, E | 1 |
Tarján, J | 2 |
Xiong, J | 3 |
Parry, G | 3 |
Adams, PC | 3 |
Chamberlain, D | 3 |
Wieczorek, I | 3 |
McBride, R | 1 |
Okubo, H | 1 |
Yasue, H | 3 |
Misumi, I | 1 |
Masuda, T | 1 |
Miyao, Y | 1 |
Sakamoto, T | 2 |
Bonnier, JJ | 1 |
Post, D | 1 |
Zateĭshchikov, DA | 2 |
Logutov, IuA | 1 |
Iavelov, IS | 1 |
Ianus, Vm | 1 |
Shalaev, SV | 2 |
Mezhetskaia, IA | 1 |
Kronmal, R | 1 |
Holdright, D | 1 |
Patel, D | 1 |
Cunningham, D | 1 |
Thomas, R | 2 |
Hubbard, W | 2 |
Hendry, G | 2 |
Sutton, G | 1 |
Fox, K | 2 |
Michel, PL | 1 |
Moise, A | 1 |
Roos, M | 1 |
Lidón, RM | 2 |
Dobrovol'skiĭ, AV | 1 |
Robitaille, D | 1 |
Boddi, M | 2 |
Martini, F | 1 |
Ieri, A | 2 |
Margheri, M | 2 |
Waters, D | 3 |
Qiu, S | 1 |
McCans, J | 3 |
de Guise, P | 1 |
Juneau, M | 3 |
Strain, J | 1 |
Keller, C | 1 |
Nyman, I | 2 |
Swahn, E | 3 |
Goodnight, SH | 1 |
Coull, BM | 1 |
McAnulty, JH | 1 |
Taylor, LM | 1 |
Yasu, T | 1 |
Oshima, S | 1 |
Imanishi, M | 1 |
Nonogi, H | 1 |
Haze, K | 1 |
Kuramochi, M | 1 |
Omae, T | 1 |
Hayashi, Y | 1 |
Yamamoto, S | 1 |
Cimminiello, C | 2 |
Soncini, M | 1 |
Casazza, F | 1 |
Langford, EJ | 1 |
Wainwright, RJ | 1 |
Castro, P | 1 |
Vergara, I | 1 |
Kunstmann, S | 1 |
Altman, R | 2 |
Rouvier, J | 1 |
Gurfinkel, E | 1 |
Turpie, AG | 5 |
Weitz, JI | 2 |
Bar Dayan, Y | 1 |
Amital, H | 2 |
Levy, Y | 2 |
Shoenfeld, Y | 2 |
Luomanmäki, K | 1 |
Eisenberg, MJ | 1 |
Topal, EJ | 1 |
Popiel, M | 1 |
Grajek, S | 1 |
Cieśliński, A | 1 |
Oler, A | 1 |
Whooley, MA | 1 |
Oler, J | 1 |
Grady, D | 1 |
Patel, DJ | 2 |
Holdright, DR | 2 |
Knight, CJ | 2 |
Mulcahy, D | 2 |
Thakrar, B | 1 |
Wright, C | 2 |
Sparrow, J | 1 |
Wicks, M | 1 |
Sutton, GC | 2 |
Purcell, H | 2 |
Breddin, HK | 2 |
Brunelli, C | 3 |
Spallarossa, P | 3 |
Rossettin, P | 1 |
Caponnetto, S | 3 |
van den Brand, MJ | 1 |
de Boer, MJ | 1 |
van Miltenburg, A | 1 |
van der Wieken, LR | 1 |
de Feyter, PJ | 1 |
Goldschmidt-Clermont, PJ | 2 |
Topol, EJ | 8 |
Navetta, FI | 1 |
Chandra, NC | 2 |
Guerci, AD | 1 |
Yakubov, SJ | 1 |
Bray, PF | 2 |
Bahr, RD | 1 |
Wolfe, CL | 1 |
Yock, PG | 1 |
Nygaard, TW | 1 |
Mason, SJ | 1 |
Effron, MB | 1 |
Fatterpacker, A | 1 |
Raskin, S | 1 |
Smith, J | 1 |
Brashears, L | 1 |
Gottdiener, P | 1 |
du Mee, C | 2 |
Kitt, MM | 3 |
Grigoryev, D | 1 |
Dise, KR | 1 |
Sagar, M | 1 |
Fox, RJ | 1 |
Coleman, LD | 1 |
Richardson, C | 1 |
Dorsey, FC | 1 |
Ouyang, P | 1 |
Baughman, KL | 1 |
Col, J | 1 |
Collins, R | 1 |
Baigent, C | 1 |
Peto, R | 1 |
Brophy, J | 1 |
Blankfield, RP | 1 |
Mattioli, AV | 1 |
Mariani, M | 1 |
Biadi, O | 1 |
Ray, J | 1 |
Lenkovsky, F | 1 |
Neirinck, LG | 1 |
Glezer, SV | 1 |
Klein, LW | 2 |
Wahid, F | 1 |
VandenBerg, BJ | 2 |
Parrillo, JE | 2 |
Calvin, JE | 2 |
Bovill, EG | 1 |
Tracy, RP | 1 |
Knatterud, GL | 1 |
Stone, PH | 1 |
Nasmith, J | 1 |
Thompson, BW | 1 |
Tofler, GH | 1 |
Kleiman, NS | 2 |
Cannon, C | 1 |
Clarke, D | 1 |
Fox, KM | 2 |
Fava, S | 1 |
Azzopardi, J | 1 |
Agius-Muscat, H | 1 |
Kher, A | 1 |
Samama, MM | 1 |
Hunziker, P | 1 |
Bertel, O | 1 |
Buchwald, A | 1 |
Hillis, SE | 1 |
Monrad, S | 1 |
Sanz, G | 1 |
van der Meer, J | 1 |
Olaisson, E | 1 |
Undeland, S | 1 |
Ludwig, K | 1 |
Simpfendorfer, C | 1 |
Kottke-Marchant, K | 1 |
Lowrie, M | 1 |
Anders, RJ | 1 |
Burns, DM | 1 |
Miller, DP | 1 |
Cove, CS | 1 |
DeFranco, AC | 1 |
Ellis, SG | 2 |
Raymond, RE | 2 |
Sutton, JM | 1 |
Williams, MJ | 2 |
Morison, IM | 1 |
Parker, JH | 1 |
Stewart, RA | 2 |
Demers, C | 1 |
Fromell, GJ | 2 |
Premmereur, J | 1 |
Bigonzi, F | 1 |
Padovano, R | 1 |
Patrono, C | 7 |
Rebuzzi, AG | 1 |
Liuzzo, G | 1 |
Quaranta, G | 1 |
Maseri, A | 3 |
Renda, G | 1 |
Voss, R | 1 |
Tillmanns, H | 1 |
Heintzen, MP | 1 |
Heidland, UE | 1 |
Klimek, WJ | 1 |
Michel, CJ | 1 |
Kelm, M | 1 |
Leschke, M | 1 |
Schwartzkopff, B | 1 |
Vester, EG | 1 |
Strauer, BE | 1 |
Machnig, T | 1 |
Rustige, J | 1 |
Gödicke, J | 1 |
Marsalek, P | 1 |
Gulba, D | 1 |
Borzak, S | 1 |
Kraft, PL | 1 |
Douthat, L | 1 |
Becker, RC | 2 |
Henry, T | 1 |
McCabe, C | 1 |
Ferrero, V | 1 |
Steffenino, G | 2 |
Meinardi, F | 1 |
Conte, E | 1 |
Deorsola, A | 1 |
Vado, A | 1 |
Racca, E | 1 |
Dellavalle, A | 1 |
Ribichini, F | 1 |
Menardi, E | 1 |
Uslenghi, E | 1 |
Bar-Dayan, Y | 1 |
Philbin, DM | 1 |
Vaccarino, V | 1 |
Murillo, JE | 1 |
Therrien, ML | 1 |
Williams, J | 1 |
Si, F | 1 |
Ouyang, M | 1 |
Sheng, C | 1 |
Every, NR | 2 |
Granger, C | 1 |
Aguirre, FV | 1 |
Talley, JD | 1 |
Booth, J | 1 |
Sapp, S | 1 |
Serruys, PW | 1 |
van Hout, B | 1 |
Bonnier, H | 1 |
Legrand, V | 1 |
Garcia, E | 1 |
Sousa, E | 1 |
van der Giessen, W | 1 |
Colombo, A | 1 |
Seabra-Gomes, R | 1 |
Kiemeneij, F | 1 |
Ruygrok, P | 1 |
Ormiston, J | 1 |
Emanuelsson, H | 1 |
Fajadet, J | 2 |
Haude, M | 1 |
Klugmann, S | 1 |
Morel, MA | 1 |
Anand, SS | 2 |
Pogue, J | 1 |
Klootwijk, P | 1 |
Meij, S | 1 |
Melkert, R | 1 |
Lenderink, T | 1 |
Habis, M | 1 |
Morice, MC | 1 |
Liron, M | 1 |
Ellis, CJ | 2 |
French, JK | 3 |
Madan, M | 1 |
Marquis, JF | 1 |
de May, MR | 1 |
Laramee, LA | 1 |
Leddy, D | 1 |
O'Brien, E | 1 |
Williams, WL | 1 |
Higginson, LA | 1 |
Jelley, J | 1 |
Reid, F | 1 |
Johansen, H | 1 |
Labinaz, M | 1 |
Bokarev, IN | 1 |
Aksenova, MB | 1 |
Khlevchuk, TV | 1 |
Dovgolis, SA | 1 |
Cairns, JA | 3 |
Ezekowitz, M | 1 |
Meade, TW | 1 |
Ivert, T | 1 |
Intonti, M | 1 |
Stain-Malmgren, R | 1 |
Dumitrescu, A | 1 |
Blombäck, M | 1 |
Mombelli, G | 1 |
Marchetti, O | 1 |
Haeberli, A | 1 |
Straub, PW | 1 |
Segal, J | 1 |
Permanyer-Miralda, G | 1 |
Brotons, C | 1 |
Calvo, F | 1 |
Campreciós, M | 1 |
Santos, MT | 1 |
Moral, I | 1 |
Soler-Soler, J | 1 |
Tuttle, RH | 2 |
Berdan, LG | 2 |
Guerci, A | 1 |
Wilcox, RG | 3 |
Eisenberg, PR | 1 |
Karsh, K | 1 |
Stepinska, J | 1 |
Boland, JB | 1 |
Tanaka, H | 1 |
Miyazaki, S | 1 |
Hattori, R | 1 |
Saito, M | 1 |
Ishikawa, K | 1 |
Masuda, Y | 1 |
Motomiya, T | 1 |
Tamura, Y | 1 |
Laskowitz, DT | 1 |
Miller, JM | 1 |
Sloan, MA | 1 |
MacAulay, CM | 1 |
Deckers, J | 1 |
Ferrario, M | 1 |
Merlini, PA | 1 |
Lucreziotti, S | 1 |
Poli, A | 1 |
Cantù, F | 1 |
Gobbi, G | 1 |
Bramucci, E | 1 |
Mussini, A | 1 |
Honye, J | 1 |
Saito, S | 1 |
Kanmatsuse, K | 1 |
Moynihan, JL | 1 |
Al-Mousa, EN | 1 |
Campsey, M | 1 |
Gandhi, R | 1 |
Mattson, S | 1 |
Ryan, KA | 1 |
Mesley, R | 1 |
Swanson, J | 1 |
Arshad, MN | 1 |
Marble, SJ | 1 |
Chai, AU | 1 |
Crawford, MH | 1 |
Tung, C | 1 |
Sauri, D | 1 |
Fintel, D | 1 |
Gheorghiade, M | 1 |
Burkhard-Meier, C | 1 |
Deutsch, HJ | 1 |
Erdmann, E | 1 |
Hyde, TA | 1 |
Straznicky, IT | 1 |
Whitlock, RM | 1 |
Smith, NL | 1 |
Reiber, GE | 1 |
Psaty, BM | 1 |
Heckbert, SR | 1 |
Siscovick, DS | 1 |
Ritchie, JL | 1 |
Koepsell, TD | 1 |
Chen, JL | 1 |
Quinn, MJ | 1 |
Fitzgerald, DJ | 2 |
Salamon, A | 1 |
Jáger, R | 1 |
Poór, F | 1 |
Barczi, V | 1 |
Dinnyés, J | 1 |
Hamvas, J | 1 |
Kinczel, A | 1 |
Pál, A | 1 |
Blaskó, G | 1 |
Iliadis, EA | 1 |
Spokas, D | 1 |
Hursey, T | 1 |
Bassand, JP | 2 |
Brener, SJ | 1 |
Creekmore, F | 1 |
Awtry, EH | 1 |
Loscalzo, J | 1 |
Karila-Cohen, D | 1 |
Gabriel Steg, P | 1 |
Angioi, M | 1 |
Alla, F | 1 |
Gangloff, C | 1 |
Sunthorn, H | 1 |
Rodriguez, RM | 1 |
Preiss, JP | 1 |
Grentzinger, A | 1 |
Houplon, P | 1 |
Juillière, Y | 1 |
Cherrier, F | 1 |
Stiefelhagen, P | 1 |
Hayes, R | 1 |
Dangas, G | 1 |
Fallon, JT | 1 |
Sharma, SK | 1 |
Coller, BS | 1 |
Badimon, L | 1 |
Marmur, JD | 1 |
Stinnett, SS | 1 |
Weatherley, BD | 1 |
Srivathsan, K | 1 |
Showalter, JC | 1 |
Hirsch, H | 1 |
Lazar, J | 1 |
Marzo, KP | 1 |
Steingart, RM | 1 |
Chen, YT | 1 |
Tuohy, ER | 1 |
Lison, L | 1 |
Vicaut, E | 1 |
Perlemuter, K | 1 |
Philippe, F | 1 |
Drobinski, G | 1 |
Brewster, GS | 1 |
Herbert, ME | 1 |
Chadow, HL | 1 |
Hauptman, RE | 1 |
VanAuker, M | 1 |
Rafii, SE | 1 |
Gunsburg, MY | 1 |
Giarraffa, L | 1 |
Strom, JA | 1 |
Ciabattoni, G | 3 |
Bucciarelli, T | 1 |
Davì, G | 2 |
Rebrov, AP | 2 |
Voskoboĭ, IV | 2 |
Miyamoto, S | 1 |
Soejima, H | 1 |
Takazoe, K | 1 |
Kajiwara, I | 1 |
Kugiyama, K | 1 |
Reeder, GS | 1 |
Walsh, CR | 1 |
Lloyd-Jones, DM | 1 |
Camargo, CA | 1 |
O'Donnell, CJ | 1 |
Alexander, J | 1 |
Pharand, C | 1 |
Barr, E | 1 |
Snapinn, S | 1 |
Ghannam, AF | 1 |
Sax, FL | 1 |
Marco, J | 1 |
Ariëns, RA | 1 |
Bossi, IM | 1 |
Marco, I | 1 |
Bernies, M | 1 |
Romano, SM | 1 |
Donatelli, F | 1 |
Brambilla, GM | 1 |
Somalvico, F | 1 |
Mari, D | 1 |
Gregorini, L | 1 |
Altman, DG | 1 |
Araujo, R | 1 |
Agustí, A | 1 |
Peter, K | 1 |
Nordt, T | 1 |
Bode, C | 1 |
Akkerhuis, KM | 1 |
Neuhaus, KL | 1 |
Vahanian, A | 1 |
Boland, JL | 1 |
Hoffmann, J | 1 |
Baardman, T | 1 |
Nehmiz, G | 1 |
Roth, U | 1 |
Klootwijk, AP | 1 |
Borja, J | 1 |
Olivella, P | 1 |
Hézard, N | 1 |
Metz, D | 1 |
Garnotel, R | 1 |
Droullé, C | 1 |
Potron, G | 1 |
Nguyen, P | 1 |
Lairikyengbam, SK | 1 |
Davies, AG | 1 |
Anderson, MH | 1 |
Sonaglia, F | 1 |
Santopinto, J | 1 |
Torres, V | 1 |
Marcos, E | 1 |
Bozovich, GE | 1 |
Ranjadayalan, K | 1 |
Storey, RF | 1 |
Oldroyd, KG | 1 |
Eto, K | 1 |
Ochiai, M | 1 |
Isshiki, T | 1 |
Takeshita, S | 1 |
Terakura, M | 1 |
Sato, T | 1 |
Ikeda, Y | 1 |
Handa, S | 1 |
Goto, S | 1 |
O'Shea, EB | 1 |
Auer, J | 1 |
Berent, R | 1 |
Maurer, E | 1 |
Mayr, H | 1 |
Weber, T | 1 |
Eber, B | 2 |
Niessner, A | 1 |
Niessner, H | 1 |
Di Minno, G | 1 |
Tufano, A | 1 |
Cerbone, AM | 1 |
Mukherjee, D | 1 |
Chew, DP | 1 |
Robbins, M | 1 |
Yadav, JS | 1 |
Vicari, R | 1 |
Frey, MJ | 1 |
Neumann, FJ | 1 |
Robertson, DH | 1 |
DeLucca, PT | 1 |
Drozdz, J | 1 |
Chrzanowski, Ł | 1 |
Kasprzak, JD | 1 |
Plewka, M | 1 |
Wierzbowska, K | 1 |
Zebrowski, MR | 1 |
Trzos, E | 1 |
Rogowski, W | 1 |
Krzemińska-Pakuła, M | 1 |
Shahi, CN | 1 |
Rathore, SS | 1 |
Thakur, R | 1 |
Wu, WC | 1 |
Lewis, JM | 1 |
Petrillo, MK | 1 |
Aroney, C | 1 |
Boyden, AN | 1 |
Jelinek, MV | 1 |
Thompson, P | 1 |
Tonkin, AM | 1 |
Stables, RH | 1 |
Lassila, R | 1 |
Fessler, HE | 1 |
Bosch, X | 1 |
Marrugat, J | 1 |
Denktas, AE | 1 |
Bayes-Genis, A | 1 |
Schwartz, RS | 1 |
Bittl, JA | 1 |
Chaitman, BR | 1 |
Feit, F | 1 |
Kimball, W | 1 |
O'Connor, FF | 1 |
Shields, DC | 1 |
Fitzgerald, A | 1 |
Albers, GW | 1 |
Amarenco, P | 1 |
Villareal, RP | 1 |
Kim, P | 1 |
Jin, L | 1 |
Campbell, P | 1 |
Rollins, G | 1 |
Morais, J | 1 |
Hacke, W | 1 |
Bahit, MC | 1 |
Blankenberg, S | 1 |
Espinola-Klein, C | 1 |
Meyer, J | 2 |
Cantor, WJ | 1 |
Christenson, RH | 1 |
Hasselblad, V | 1 |
Gibson, M | 1 |
Rush, JE | 1 |
Sanderink, G | 1 |
Ball, SP | 1 |
Hand, MH | 1 |
Bahr, R | 1 |
Christenson, R | 1 |
Eagle, K | 1 |
Lambrew, CT | 1 |
Lee, TH | 1 |
MacLeod, B | 1 |
Ornato, JP | 1 |
Selker, HP | 1 |
Steele, P | 1 |
Zalenski, RJ | 1 |
Harding, SA | 1 |
Boon, NA | 1 |
Flapan, AD | 1 |
Dimas, AP | 1 |
Luciardi, HL | 1 |
Muntaner, J | 1 |
Del Rio, F | 1 |
Berman, SG | 1 |
Lopez, R | 1 |
Gonzalez, C | 1 |
Balsano, F | 2 |
Violi, F | 2 |
Censi, C | 1 |
Amanullah, AM | 1 |
Lindvall, K | 1 |
Grambow, DW | 1 |
Manske, CL | 1 |
Rector, T | 1 |
Wilson, RF | 1 |
White, CW | 1 |
Schreiber, TL | 3 |
Rizik, D | 1 |
White, C | 1 |
Sharma, GV | 1 |
Cowley, M | 2 |
Macina, G | 3 |
Reddy, PS | 1 |
Kantounis, L | 1 |
Timmis, GC | 1 |
Margulis, A | 1 |
Lam, JY | 1 |
Ramires, JA | 2 |
McAnally, LE | 1 |
Corn, CR | 1 |
Hamilton, SF | 1 |
Presbitero, P | 1 |
Rabajoli, F | 1 |
Paolillo, V | 1 |
Lam, J | 1 |
Violaris, AG | 1 |
Campbell, S | 1 |
Ghigliotti, G | 1 |
Lantieri, P | 1 |
Iannetti, M | 1 |
Gulba, DC | 1 |
Mahon, J | 1 |
Steel, K | 1 |
Feagan, BG | 1 |
Laupacis, A | 1 |
Pederson, LL | 1 |
Nylander, E | 1 |
Merino, A | 1 |
Hawkins, L | 1 |
Greenberg, S | 1 |
Wallentin, LC | 1 |
Trotta, F | 1 |
Casolo, GC | 1 |
Bini, M | 1 |
Bleifeld, W | 1 |
Morrison, DA | 1 |
Aursnes, I | 1 |
Osnes, JB | 1 |
Platou, ES | 1 |
Smiseth, OA | 1 |
Amlie, JP | 1 |
Nielsen, JD | 1 |
Stoltenberg, M | 1 |
Juul, A | 1 |
Siemsen, M | 1 |
Christiansen, IB | 1 |
Hosoda, S | 1 |
Uchida, T | 1 |
Boudoulas, H | 1 |
Atakhanova, LZ | 1 |
Mazurov, AV | 1 |
Katsenovich, ER | 1 |
Karpov, IuA | 1 |
Kostko, SZ | 1 |
Repin, VS | 1 |
Ruda, MIa | 1 |
Born, GV | 2 |
Patscheke, H | 1 |
Hornberger, W | 1 |
Zehender, H | 1 |
Roberts, R | 1 |
Joelson, JM | 1 |
Degré, SG | 1 |
Fang, ZY | 1 |
Sobolski, J | 1 |
Abramowicz, M | 1 |
Unger, P | 1 |
Berkenboom, G | 1 |
Boem, A | 1 |
Gazzetti, P | 1 |
Sicari, R | 1 |
Giannessi, D | 1 |
Rutherford, JD | 1 |
Chard, RB | 1 |
Kam, CA | 1 |
Nunn, GR | 1 |
Johnson, DC | 1 |
Meldrum-Hanna, W | 1 |
Charvát, J | 2 |
Fiserová, J | 1 |
Hockings, B | 1 |
Cox, RA | 1 |
Penkov, N | 1 |
Sirakova, V | 1 |
Kristensen, SD | 1 |
Bath, PM | 1 |
Vejar, M | 2 |
Fragasso, G | 1 |
Hackett, D | 2 |
Lipkin, DP | 1 |
Bunnell, P | 2 |
Tenney, RD | 1 |
McNulty, A | 2 |
Kikel, M | 2 |
Miller, DH | 2 |
Zola, BE | 1 |
Tracy, R | 1 |
Stump, D | 1 |
Ianetti, M | 1 |
Galassi, AR | 1 |
Lipkin, D | 1 |
Oates, JA | 1 |
von Dohlen, TW | 1 |
Rogers, WB | 1 |
Frank, MJ | 1 |
Silberberg, JS | 1 |
McGregor, M | 1 |
Kuruvilla, T | 1 |
Fluch, N | 1 |
Dusleag, J | 1 |
Weinrauch, V | 1 |
Rotman, B | 1 |
Gasser, R | 1 |
Kronberger-Schaffer, E | 1 |
Castaigne, A | 1 |
Duval-Moulin, AM | 1 |
Dutoit, C | 1 |
Devereux, RB | 1 |
Tenney, R | 1 |
Zola, B | 1 |
Borhani, NO | 1 |
Hugenholtz, PG | 1 |
Cohen, LS | 1 |
Luchi, RJ | 1 |
Scott, SM | 1 |
Deupree, RH | 1 |
Leeman, DE | 1 |
Faxon, DP | 1 |
Lorell, BH | 1 |
Kellett, MA | 1 |
McKay, RG | 1 |
Varricchione, T | 1 |
Baim, DS | 1 |
Seth, A | 1 |
Perry, RA | 1 |
Shiu, MF | 1 |
Slany, J | 1 |
Hamad, JF | 1 |
Wittes, J | 1 |
Friedman, L | 1 |
Ouimet, H | 1 |
Latour, JG | 1 |
Joly, P | 1 |
Lévy, G | 1 |
Pelletier, E | 1 |
Stasiak, J | 1 |
deGuise, P | 1 |
Petch, MC | 1 |
Panetta, A | 1 |
Pinto, S | 1 |
Favilla, S | 1 |
Rehr, RB | 1 |
DiSciascio, G | 1 |
Cowley, MJ | 1 |
Hansen, JF | 1 |
Hansen, BF | 1 |
Resnekov, L | 1 |
Chediak, J | 1 |
Lewis, D | 1 |
Nicolas, G | 1 |
Orlov, VA | 1 |
Iakunin, GA | 2 |
Khishtovani, AI | 2 |
Bates, ER | 1 |
Mickelson, JK | 1 |
Winniford, M | 1 |
Dmitriev, AA | 1 |
Kormer, AIa | 1 |
Oelz, O | 1 |
Gent, M | 1 |
Singer, J | 1 |
Finnie, KJ | 1 |
Froggatt, GM | 1 |
Holder, DA | 1 |
Jablonsky, G | 1 |
Kostuk, WJ | 1 |
Melendez, LJ | 1 |
Myers, MG | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients[NCT01171404] | 10,568 participants (Actual) | Observational | 2010-09-30 | Completed | |||
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998] | Phase 3 | 9,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome[NCT00831441] | Phase 3 | 7,484 participants (Actual) | Interventional | 2009-03-31 | Terminated | ||
Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease[NCT05122455] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785] | 90 participants (Actual) | Observational | 2017-03-27 | Completed | |||
Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain[NCT00869245] | 124 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
Randomized Investigation of Chest Pain Diagnostic Strategies[NCT01035047] | 105 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
Randomized Cost Comparison of Cardiac MRI Use in ED Patients With Chest Pain[NCT00678639] | 110 participants (Actual) | Interventional | 2008-01-31 | Completed | |||
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
[NCT00000614] | Phase 3 | 0 participants | Interventional | 1998-09-30 | Completed | ||
Variation Between Hospitals in Short-term Mortality After Acute Coronary Syndromes: A CALIBER Study[NCT01111071] | 316,648 participants (Actual) | Observational | 2010-04-30 | Completed | |||
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
Clinical Feature and Outcome of Angiographic Coronary Artery Disease in Chronic Kidney Disease Patients[NCT00651521] | 1,000 participants (Actual) | Observational | 2009-04-30 | Active, not recruiting | |||
Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin[NCT01931852] | 312 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
[NCT00000472] | Phase 3 | 0 participants | Interventional | 1989-04-30 | Completed | ||
Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation[NCT02159287] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures[NCT05292846] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-01-20 | Recruiting | ||
The Effect of Serum LDL Lowering on Aspirin Resistance[NCT00466154] | 40 participants | Interventional | 2005-07-31 | Completed | |||
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
A Clinical Trial of Conservative Versus Routine Invasive Management in Patients With Prior Coronary Artery Bypass Surgery in Patients With a Non-ST Elevation Acute Coronary Syndrome: a Pilot Trial and Registry.[NCT01895751] | Phase 4 | 60 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
Intervention | percentage of participants with an event (Number) |
---|---|
Prasugrel: <75 Years of Age | 10.61 |
Prasugrel: 75 Years of Age or Older | 27.04 |
Clopidogrel: <75 Years of Age | 11.12 |
Clopidogrel: 75 Years of Age or Older | 26.83 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
Intervention | percentage of participants with an event (Number) |
---|---|
Prasugrel: <75 Years of Age | 10.06 |
Prasugrel: 75 Years of Age or Older | 24.64 |
Clopidogrel: <75 Years of Age | 10.96 |
Clopidogrel: 75 Years of Age or Older | 24.13 |
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
Intervention | percentage of participants with an event (Number) |
---|---|
Prasugrel: <75 Years of Age | 9.61 |
Prasugrel: 75 Years of Age or Older | 22.53 |
Clopidogrel: <75 Years of Age | 10.21 |
Clopidogrel: 75 Years of Age or Older | 22.69 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
Intervention | percentage of participants with an event (Number) |
---|---|
Prasugrel: <75 Years of Age | 12.13 |
Prasugrel: 75 Years of Age or Older | 26.27 |
Clopidogrel: <75 Years of Age | 12.83 |
Clopidogrel: 75 Years of Age or Older | 25.67 |
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months
Intervention | picograms per milliliter (pg/mL) (Geometric Mean) | |
---|---|---|
Day 30 | 6 Months (n=725, 125, 701, 174) | |
Clopidogrel: <75 Years of Age | 319.345 | 250.982 |
Clopidogrel: 75 Years of Age or Older | 951.359 | 722.750 |
Prasugrel: <75 Years of Age | 313.494 | 253.434 |
Prasugrel: 75 Years of Age or Older | 1082.396 | 770.132 |
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6
Intervention | milligrams per liter (mg/L) (Geometric Mean) | |
---|---|---|
Day 30 | 6 Months (n=755, 143, 745, 178) | |
Clopidogrel: <75 Years of Age | 2.287 | 2.149 |
Clopidogrel: 75 Years of Age or Older | 2.226 | 1.543 |
Prasugrel: <75 Years of Age | 2.330 | 2.272 |
Prasugrel: 75 Years of Age or Older | 2.441 | 1.593 |
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Baseline, physical limitations | Baseline, angina frequency | 24 Months, physical limitations (n=420, 412) | 24 Months, angina frequency (n=420, 412) | |
Clopidogrel | 67.0 | 73.1 | 74.5 | 89.5 |
Prasugrel | 67.8 | 73.6 | 75.1 | 89.7 |
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline
Intervention | percentage participants with geneotype (Number) | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UM, *1/*17 | UM, *17/*17 | EM (non-UM), *1/*1 | IM, *1/*2 | IM, *1/*3 | IM, *1/*4 | IM, *1/*6 | IM, *1/*8 | PM, *2/*2 | PM, *2/*3 | PM, *2/*4 | PM, *2/*6 | PM, *2/*8 | PM, *3/*3 | UNK, *1/*10 | UNK, *1/*13 | UNK, *1/*9 | UNK, *1/*9, *9/*17 | UNK, *13/*17 | UNK, *2/*13 | UNK, *2/*17 | UNK, *2/*9 | UNK, *3/*17 | UNK, *4/*17 | UNK, *4/*9 | UNK, *6/*17 | UNK, *8/*17 | UNK, *9/*17 | UNK, Undefined genotype | |
Clopidogrel: <75 Years of Age | 25.1 | 5.4 | 35.7 | 19.8 | 0.5 | 0.1 | 0.0 | 0.4 | 4.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.8 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.5 |
Clopidogrel: 75 Years of Age or Older | 21.8 | 4.3 | 41.2 | 19.7 | 0.6 | 0.3 | 0.2 | 0.3 | 3.8 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.6 |
Prasugrel: <75 Years of Age | 24.0 | 5.1 | 38.8 | 18.6 | 0.8 | 0.4 | 0.0 | 0.1 | 3.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 6.3 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.7 |
Prasugrel: 75 Years of Age or Older | 25.0 | 3.6 | 42.1 | 18.3 | 0.6 | 0.0 | 0.2 | 0.5 | 2.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months
Intervention | P2Y12 Reaction Units (PRU) (Least Squares Mean) | |
---|---|---|
Day 30 | Month 12 (n=386, 76, 400, 103) | |
Clopidogrel: <75 Years of Age | 193.489 | 199.003 |
Clopidogrel: 75 Years of Age or Older | 200.285 | 181.360 |
Prasugrel: <75 Years of Age | 93.280 | 94.529 |
Prasugrel: 75 Years of Age or Older | 151.872 | 135.096 |
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
Intervention | participants (Number) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Congestive Heart Failure | Cardiogenic Shock | Cardiac Rupture | Myocardial Infarction | Dysrhythmia | Stent Thrombosis | Directly Related to Revascularization-CABG or PCI | Intracranial Hemorrhage | Non-Hemorrhagic Stroke | Sudden death due to cardiovascular event | Pulmonary Embolism | Stroke, unknown type | Other Cardiovascular Event | Cardiovascular event, unknown type | Accidental | Trauma | Hemorrhage, not intracranial | Infection | Malignancy | Suicide | Other Non-Cardiovascular event | Cause unknown (nonadjudicated event) | |
Clopidogrel: <75 Years of Age | 13 | 10 | 0 | 24 | 6 | 0 | 1 | 4 | 4 | 70 | 2 | 0 | 0 | 45 | 1 | 0 | 0 | 16 | 14 | 0 | 8 | 0 |
Clopidogrel: 75 Years of Age or Older | 23 | 9 | 0 | 21 | 3 | 0 | 1 | 1 | 3 | 43 | 1 | 0 | 1 | 45 | 1 | 1 | 4 | 17 | 11 | 0 | 6 | 0 |
Prasugrel: <75 Years of Age | 10 | 8 | 0 | 16 | 5 | 0 | 1 | 2 | 4 | 75 | 0 | 0 | 6 | 40 | 1 | 2 | 1 | 14 | 14 | 1 | 8 | 0 |
Prasugrel: 75 Years of Age or Older | 21 | 4 | 1 | 24 | 2 | 0 | 1 | 1 | 4 | 39 | 1 | 1 | 1 | 41 | 0 | 3 | 1 | 21 | 7 | 0 | 4 | 1 |
Bleeding events were adjudicated by the Adjudication Committee and classified according to Thrombolysis in Myocardial Infarction (TIMI) major, minor, minimal, and International Society on Thrombosis and Hemostasis (ISTH) major and clinically relevant non-major bleeding (CRNM) criteria. The adjudicated results based on TIMI and ISTH classifications, and programmatically identified events (not adjudicated) according to Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification were used in the analyses of bleeding endpoints. GUSTO Bleed Criteria included Severe or life-threatening: Intracranial hemorrhage, or bleeding that causes hemodynamic compromise requiring intervention; Moderate: Bleeding that requires a blood transfusion, but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either severe or moderate bleeding. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (Bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
Intervention | percentage of participants/100-pt years (Number) |
---|---|
Placebo | 16.33 |
Apixaban 5 mg BID | 39.98 |
Event rate was percent of participants with an event of cardiovascular (CV) death, myocardial infarction (MI), or ischemic stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Study was terminated early and last patient, last visit was in Year 2. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes (eg, cardiogenic shock, heart failure, arrhythmia/sudden death, cardiac rupture, ischemic stroke, pulmonary embolism, venous/arterial thrombotic events) and other sudden deaths for which an alternative cause was not identified. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, MI, ischemic stroke), up to March 2011, approximately 2 years
Intervention | percentage of participants/100-pt years (Number) |
---|---|
Placebo | 13.96 |
Apixaban 5 mg BID | 13.20 |
"Cause of death was determined by the principal condition that caused the death, not the immediate mode of death.~CV death: included deaths due to CV causes. Non-CV death: included non-CV deaths caused primarily by a malignancy, infection, bleeding, trauma, non-CV system organ failure, or non-CV surgery. Unknown: included deaths that were not attributable to one of the above categories of CV death or to a non-CV cause. MI accounted whether the participant had a recent PCI or CABG surgery. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause. Only events confirmed by the adjudication committee were included in analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination)." (NCT00831441)
Timeframe: Randomization (Day 1) to first event (All Cause Death, MI, or Stroke), up to March 2011, approximately 2 years
Intervention | percentage of participants/100-pt years (Number) |
---|---|
Placebo | 15.65 |
Apixaban 5 mg BID | 15.48 |
Event rate was percent of participants with an event of CV death, fatal bleed, MI, or stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes; Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause; Fatal bleeding defined as bleeding that Adjudication Committee determined was the primary cause of death or contributed directly to death; MI took into account whether the participant had a recent PCI or CABG surgery. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, Fatal Bleed, MI, or stroke), up to March 2011, approximately 2 years
Intervention | percentage of participants/100-pt years (Number) |
---|---|
Placebo | 14.27 |
Apixaban 5 mg BID | 13.97 |
Event rate was percent of participants with an event of CV death, MI, unstable angina (UA), or ischemic stroke (number of participants with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Each type of event was counted once per participant, but participants could have been counted in multiple categories. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, MI, UA, Ischemic Stroke, up to March 2011, approximately 2 years
Intervention | percentage of participants/100-pt years (Number) |
---|---|
Placebo | 17.95 |
Apixaban 5 mg BID | 16.92 |
ISTH Major bleed: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed RBCs; Bleeding that occurs in at least one of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. CRNM: acute clinically overt bleeding that did not satisfy additional criteria required for the bleeding event to be defined as a major bleeding event and meets at least one of the following: Hospital admission for bleeding; Physician guided medical or surgical treatment for bleeding; Change in anti-thrombotic treatment (anticoagulant or antiplatelet) therapy. Bleeding events were adjudicated by the Adjudication Committee. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (ISTH major or CRNM bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
Intervention | percentage of participants/100-pt years (Number) |
---|---|
Placebo | 2.29 |
Apixaban 5 mg BID | 6.15 |
ISTH Criteria: Acute clinically overt bleeding defined as new onset, visible bleeding or signs or symptoms suggestive of bleeding confirmed by imaging techniques, which can detect the presence of blood (eg, ultrasound, CT, MRI). Major bleeding: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed red blood cells (RBCs); Bleeding that occurs in at least one of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. Bleeding events were adjudicated by the Adjudication Committee. Event rate was percent of participants with an event (number with event/number randomized) per 100-pt years. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (ISTH major bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
Intervention | percentage of participants/100-pt years (Number) |
---|---|
Placebo | 2.04 |
Apixaban 5 mg BID | 5.13 |
TIMI Major Bleed Criteria: Fatal bleeding, intracranial hemorrhage, and clinically overt bleeding with a hemoglobin (Hgb) drop of ≥ 5 grams per deciliter (g/dL), or ≥15% absolute decrease in hematocrit. To account for transfusions, Hgb measurements were adjusted for transfusions. A transfusion of 1 unit of blood was assumed to result in an increase by 1 g/dL in Hgb or 3% in hematocrit. Event rate was percent of participants with an event of Major Bleed as per TIMI (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (TIMI major bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
Intervention | percentage of participants/100-pt years (Number) |
---|---|
Placebo | 0.91 |
Apixaban 5 mg BID | 2.40 |
MI took into account whether the participant had a recent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. Selected key criteria: Elevation of cardiac biomarkers (eg, Creatine Kinase MB fraction (CKMB), Troponin T, Troponin I) above the upper reference limit (URL) plus ischemic symptoms, ECG changes, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; Death of CV etiology with new ST-segment elevation or left bundle branch block (LBBB) or fresh intracoronary thrombus by angiography or at autopsy occurring before biomarkers could be obtained or before their appearance in the blood; Following a PCI, elevation of cardiac biomarkers more than 3*URL; Following CABG surgery, elevation of cardiac biomarkers more than 5*URL; New, significant (≥0.04 s) Q waves in ≥2 contiguous leads; Pathologic findings of acute MI. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice. (NCT00831441)
Timeframe: Randomization (Day 1) to first event (MI), up to March 2011, approximately 2 years
Intervention | percentage of participants/100-pt years (Number) |
---|---|
Placebo | 9.20 |
Apixaban 5 mg BID | 8.59 |
Stent thrombosis: Definite stent thrombosis considered to have occurred by either angiographic or pathological confirmation; Probable stent thrombosis considered to have occurred in the following cases: any unexplained death within the first 30 days after stent implantation; irrespective of the time after the procedure, any MI that was related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause; Possible stent thrombosis considered to have occurred with any unexplained death from 30 days after intracoronary stenting until end of study (in Year 2). Event rate was percent of participants with an event of stent thrombosis (number with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice of study termination. (NCT00831441)
Timeframe: Randomization (Day 1) to first event (stent thrombosis), up to March 2011, approximately 2 years
Intervention | percentage of participants/100-pt years (Number) |
---|---|
Placebo | 2.21 |
Apixaban 5 mg BID | 1.61 |
Event rate was percent of participants with an event of stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause (ie, brain tumor). All strokes were classified as hemorrhagic (documentation on imaging (eg computed tomography scan or magnetic resonance imaging) of hemorrhage in the cerebral parenchyma, or a subdural or subarachnoid hemorrhage), non-hemorrhagic/ischemic stroke, ischemic stroke with hemorrhagic conversion, or type unknown. Intended Treatment Period: the period that started on the day of randomization (Day 1) and ended at the efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (stroke), up to March 2011, approximately 2 years
Intervention | percentage of participants/100-pt years (Number) |
---|---|
Placebo | 1.85 |
Apixaban 5 mg BID | 1.65 |
Unstable Angina (UA) defined as worsening or recurrent severe or repetitive angina symptoms at rest lasting at least 10 minutes with at least 2 of the following: New and dynamic electrocardiogram (ECG) changes; angina symptoms leading to inpatient hospitalization; angina symptoms leading to an unplanned or urgent cardiac catheterization, with or without revascularization, that showed evidence of hemodynamically and clinically significant stenosis. Event rate was percent of participants with an event of unstable angina (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010). (NCT00831441)
Timeframe: Randomization (Day 1) to first event of UA, up to March 2011, approximately 2 years
Intervention | percentage of participants/100-pt years (Number) |
---|---|
Placebo | 4.21 |
Apixaban 5 mg BID | 3.95 |
(NCT00228423)
Timeframe: 1 year
Intervention | Participants (Count of Participants) |
---|---|
75mg Clopidogrel | 4 |
Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
Intervention | Participants (Count of Participants) |
---|---|
75mg Clopidogrel | 1 |
Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
Intervention | percentage (Number) |
---|---|
75mg Clopidogrel | 94.3 |
Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
Intervention | mm (Mean) |
---|---|
75mg Clopidogrel | 4.1 |
Placebo | 4.5 |
(NCT01035047)
Timeframe: Index Hospitalization discharge through 90 days
Intervention | participants (Number) |
---|---|
CDU-CMR Protocol | 0 |
Inpatient Care | 3 |
(NCT01035047)
Timeframe: Duration of Index Hospitalization, an average of 1-2 days
Intervention | hours (Median) |
---|---|
CDU-CMR Protocol | 21.1 |
Inpatient Care | 26.3 |
(NCT01035047)
Timeframe: Index Hospitalization through 90 days
Intervention | participants (Number) |
---|---|
CDU-CMR Protocol | 0 |
Inpatient Care | 0 |
(NCT01035047)
Timeframe: Index Hospitalization through 90 days
Intervention | participants (Number) |
---|---|
CDU-CMR Protocol | 1 |
Inpatient Care | 0 |
(NCT01035047)
Timeframe: Index Hospitalization through 90 days
Intervention | participants (Number) |
---|---|
CDU-CMR Protocol | 7 |
Inpatient Care | 20 |
Any event leading to early termination of the MRI acquisition, or requiring intervention by a physician, will be considered an adverse event related to MRI, excluding physician termination of image acquisition due to concerns of cardiac ischemia. (NCT00678639)
Timeframe: Occuring in the MRI scanning suite or within 30 minutes of the last image acquisition.
Intervention | Participants (Number) |
---|---|
Emergency Department (ED) Observation Unit | 3 |
Usual Care | 1 |
Participants with ACS and admitted or not experiencing ACS and discharged will be considered a correct admission decision. Remaining participants will be considered to have incorrect admission decisions. (NCT00678639)
Timeframe: 30 Days
Intervention | Participants (Number) |
---|---|
Emergency Department (ED) Observation Unit | 43 |
Usual Care | 6 |
Index hospitalization refers to the hospital visit during which the participant was enrolled in the trial. The primary outcome is examining the cost for this visit. (NCT00678639)
Timeframe: Emergency Department (ED) arrival through hospital discharge, median length of stay was 28.1 hours
Intervention | US Dollars (Median) |
---|---|
Emergency Department (ED) Observation Unit | 2062 |
Usual Care | 2680 |
The number of participants able to complete the planned imaging sequences will be measured. (NCT00678639)
Timeframe: Emergency Department (ED) arrival through hospital discharge
Intervention | Participants (Number) |
---|---|
Emergency Department (ED) Observation Unit | 46 |
Measured as self report, assessed during telephone follow-up. (NCT00678639)
Timeframe: 30d, 3mo, 6mo, and 1 year
Intervention | Participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Cardiac related office visit | Cardiac related ED visit | Cardiac related hospitalization | Cardiac related procedures | Cardiac Catheterization | Stress Test | Resting Echocardiogram | |
Emergency Department (ED) Observation Unit | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
Usual Care | 4 | 4 | 3 | 4 | 3 | 1 | 1 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
Intervention | Participants (Number) |
---|---|
Prasugrel | 692 |
Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
Intervention | Participants (Number) |
---|---|
Prasugrel | 797 |
Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
Intervention | Participants (Number) | |
---|---|---|
All ACS (Through 30 days) | All ACS (Through 90 days) | |
Clopidogrel | 502 | 573 |
Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
Intervention | Participants (Number) | ||
---|---|---|---|
UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
Clopidogrel | 565 | 216 | 781 |
Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
Intervention | Participants (Number) | |
---|---|---|
All ACS (Through 30 days) | All ACS (Through 90 days) | |
Clopidogrel | 504 | 588 |
Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
Intervention | Participants (Number) | ||||||||
---|---|---|---|---|---|---|---|---|---|
TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
155 reviews available for aspirin and Angina, Unstable
Article | Year |
---|---|
The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Canada; Clopidogrel; Drug Therapy, Combination; | 2022 |
Use of antiplatelet drugs in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clinical Trials as Topi | 2013 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrh | 2014 |
Role of platelet inhibition in microvascular surgery.
Topics: Angina, Unstable; Aspirin; Coronary Disease; Endothelium, Vascular; Free Tissue Flaps; Humans; Plate | 2014 |
Review of acute coronary syndromes: diagnosis and management of unstable angina and non ST-elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angina, Unstable; Angiotensin-Converting Enzym | 2015 |
Advances in antiplatelet therapy for ACS and PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angina, Unstable; Aspirin; Blood Platelets; Cardia | 2008 |
Acute coronary syndrome (unstable angina and non-ST elevation MI).
Topics: Acute Coronary Syndrome; Acute Disease; Administration, Oral; Angina, Unstable; Aspirin; Calcium Cha | 2009 |
[Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticoagulants; Aspirin; Evidence-Based Medicine; Fibrino | 2010 |
P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Humans; Integrin alpha2; Myocardial I | 2011 |
[Acute myocardial infarction: diagnosis and treatment].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Electrocardiography; Emer | 2011 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary | 2012 |
Antiplatelet agents in ischemic heart disease.
Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascular | 2012 |
Unstable angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin, Low-Molecular-We | 2002 |
[Treatment of coronary insufficiency in diabetics: Part 2: acute coronary insufficiency].
Topics: Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon, Coronary; Angiot | 1999 |
Contemporary view of the acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease | 2003 |
Unstable angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin, Low-Molecular-We | 2002 |
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
Topics: Acute Disease; Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clop | 2003 |
[Role of low-molecular-weight heparin in acute coronary syndromes].
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Drug Administration Sche | 2002 |
Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid | 2002 |
Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks.
Topics: Angina, Unstable; Aspirin; Coronary Disease; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ri | 2003 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Ant | 2003 |
Angina (unstable).
Topics: Angina, Unstable; Aspirin; Clopidogrel; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation | 2003 |
The role of clopidogrel in the management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; C | 2003 |
Treatment of unstable angina pectoris/non-ST-segment elevation myocardial infarction in elderly patients.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Antic | 2003 |
Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Drug Resistance; Eicosanoids; Humans; Isoprostan | 2003 |
Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial.
Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Dalteparin; Drug Therapy, Combination; Fibrinolytic | 2002 |
Recent clinical trial results with antiplatelet therapy: implications in stroke prevention.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Pla | 2004 |
[Drug therapy for patients with unstable angina].
Topics: Abciximab; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Aspirin; Calcium C | 2004 |
Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Clinical Trials as Topi | 2003 |
Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemor | 2004 |
Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Heparin, Low-Molecular | 2004 |
Combined antithrombotic therapy for acute coronary syndrome.
Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; D | 2003 |
Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Hemorrhage; Humans; | 2004 |
Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Humans; Hypercholesterolemia | 2004 |
Platelet function testing in cardiovascular diseases.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Case Management; Clopidogrel; Drug Resistance; H | 2004 |
Acute coronary syndromes: pathogenesis, acute diagnosis with risk stratification, and treatment.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Exercise Test; Heparin; Hu | 2004 |
Angina (unstable).
Topics: Angina, Unstable; Aspirin; Cardiac Catheterization; Heparin, Low-Molecular-Weight; Humans; Platelet | 2003 |
Variability in response to aspirin: do we understand the clinical relevance?
Topics: Acute Disease; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials a | 2005 |
Issues in the management of antiplatelet therapy in patients undergoing surgical revascularization. A roundtable discussion.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; C | 2005 |
Clopidogrel in acute coronary syndrome: when, how much, how long?
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; D | 2005 |
[Acute chest pain].
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Algorithms; Angina, Unstable; Angioplasty, Balloon | 2005 |
Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; | 2006 |
Best evidence topic report. Clopidogrel plus aspirin or aspirin alone in unstable angina.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhi | 2006 |
[Secondary prevention of acute coronary syndromes: are we following correctly the guidelines?].
Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Angina, Unstable; Angiotensin-Converting Enz | 2006 |
[Anti-platelet drugs (aspirin, ticlopidine, etc)].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Humans; Meta-An | 2006 |
[Acute coronary syndrome risk management].
Topics: Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Artery Disease; Humans | 2006 |
[Antiplatelet therapy in acute coronary syndromes without ST segment elevation].
Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet | 2006 |
Angina (unstable).
Topics: Angina, Unstable; Aspirin; Cardiac Catheterization; Clopidogrel; Heparin, Low-Molecular-Weight; Huma | 2005 |
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
Topics: Angina, Unstable; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Humans; Inflam | 2007 |
Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Th | 2007 |
[Unstable angina].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon, Corona | 2007 |
Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Evidence-B | 2007 |
[Therapy of chronic stable angina].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Aspirin; | 2008 |
Translational therapeutics at the platelet vascular interface. Summary.
Topics: Angina, Unstable; Animals; Aspirin; Blood Platelets; Clopidogrel; Disease Models, Animal; Drug Evalu | 2008 |
Mechanisms contributing to precipitation of unstable angina and acute myocardial infarction: implications regarding therapy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon; Animals; Antic | 1984 |
Percutaneous transluminal coronary angioplasty.
Topics: Angina, Unstable; Angioplasty, Balloon; Animals; Aspirin; Calcium Channel Blockers; Coronary Artery | 1984 |
New directions in anticoagulant and antiplatelet treatment.
Topics: Angina, Unstable; Aspirin; Chronic Disease; Drug Therapy, Combination; Humans; Myocardial Infarction | 1995 |
Cardiology--I: Treatment of myocardial infarction, unstable angina, and angina pectoris.
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 1994 |
[Coronary disease: benefits of aspirin. What dose for which disease?].
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Female; | 1994 |
Unstable angina: pathogenesis, diagnosis, and treatment.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Calcium Chan | 1993 |
Antiplatelet therapy--Part I.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronar | 1993 |
[Blood platelet aggregation inhibitors in the treatment of heart diseases].
Topics: Angina, Unstable; Aspirin; Coronary Artery Disease; Coronary Disease; Dipyridamole; Humans; Platelet | 1993 |
[The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?].
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarc | 1995 |
Oral anticoagulant treatment with and without aspirin.
Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridam | 1995 |
Advances in antithrombotic therapy: novel agents.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombins; Aspirin; Clinical Trials as Topic; | 1995 |
[Treatment of unstable angina pectoris].
Topics: Adrenergic beta-Antagonists; Algorithms; Angina, Unstable; Aspirin; Calcium Channel Blockers; Drug T | 1995 |
Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction.
Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Hospitalization; Humans; Myocardial In | 1996 |
[Contemporary opinions on the use of aspirin, heparin and thrombolytic therapy in unstable angina pectoris--pathogenetic findings versus results of many clinical tests].
Topics: Angina, Unstable; Angiography; Aspirin; Hemorrhage; Heparin; Humans; Thrombolytic Therapy; Thrombosi | 1996 |
Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Hemorrhage; He | 1996 |
Coronary heart disease, unstable angina, PTCA: new indications for low molecular weight heparins?
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Coronary Disease | 1996 |
Recognition and treatment of unstable angina.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Guidelines as Topic; Humans; Platelet Aggreg | 1996 |
Low molecular weight heparins: a valuable tool in the treatment of acute coronary syndromes.
Topics: Angina, Unstable; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Heparin, Low-Mol | 1996 |
[Clinical studies of the effectiveness of aspirin in the prevention of major cardio-cerebrovascular occurrences].
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Myocardial I | 1995 |
[The use of acetylsalicylic acid in IHD].
Topics: Angina, Unstable; Aspirin; Coronary Vessels; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 1996 |
[Low molecular weight heparin in unstable angina].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Dose-Response Relationship, Drug; Drug Therap | 1996 |
Unmet therapeutic needs in the management of acute ischemia.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Fibrinolytic Agents; Humans; Myo | 1997 |
Platelet activation and inhibition in unstable coronary syndromes.
Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation | 1997 |
[Current aspects of thrombolytic therapy in unstable angina pectoris].
Topics: Angina, Unstable; Aspirin; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Platelet Gl | 1997 |
New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Hematologic Agents; Heparin; He | 1998 |
Clinical potential of antithrombotic drugs in coronary syndromes.
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1998 |
[Antithrombotic agents in unstable angina. Review of clinical trials].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hirudin | 1998 |
Treatment options in unstable angina: a clinical update.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Electroca | 1998 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Coronary Thrombosis; Fibrinolytic Agent | 1998 |
Antithrombotic therapy of unstable angina and non-Q-wave myocardial infarction.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Aspirin; Fibrinolytic Agents; H | 1999 |
[Conservative management in patients with acute coronary syndrome].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; | 1999 |
Low molecular weight heparins in the cardiac catheterization laboratory.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 1999 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti | 1999 |
"Traditional" medical therapy for unstable angina. How important? How to use?
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Anticoagulants; Aspirin; Calcium Channel Blockers; He | 1999 |
Management of high-risk subsets in unstable angina.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Atherectomy, Coronary; Calcium Channel Bl | 1999 |
[Current therapy for unstable angina pectoris].
Topics: Angina, Unstable; Anti-Bacterial Agents; Anticholesteremic Agents; Anticoagulants; Antithrombins; As | 1999 |
Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarc | 1999 |
Anticoagulants in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease | 1999 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bo | 1999 |
[Angioplasty in unstable chest angina. Angioplasty in unstable angina].
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti-Inflammatory Age | 1999 |
Unfractionated and low-molecular-weight heparins in acute coronary syndromes: current recommendations.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Enoxaparin; F | 2000 |
Long-term management--the way forward?
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Dalteparin; Drug Therapy, Combin | 2000 |
Targeting treatment for optimal outcome.
Topics: Age Factors; Aged; Angina, Unstable; Anticoagulants; Aspirin; Biomarkers; Clinical Protocols; Daltep | 2000 |
Aspirin.
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Digestive System; Humans; Myocardial Infarctio | 2000 |
[Aspirin and prevention of cardiovascular risk].
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Ste | 2000 |
Percutaneous revascularization for unstable angina in the elderly.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagu | 2000 |
Anti-thrombotic therapy for elderly patients with acute coronary syndromes.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Heparin; Heparin, Low-Molecular-Weight; Humans; Myocardia | 2000 |
Oral platelet glycoprotein IIb/IIIa inhibition.
Topics: Alanine; Angina, Unstable; Aspirin; Benzamidines; Clinical Trials, Phase II as Topic; Clinical Trial | 2000 |
Contemporary diagnosis and management of unstable angina.
Topics: Abciximab; Acute Disease; Algorithms; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, | 2000 |
Clinical trials of unfractionated heparin and low-molecular-weight heparin in addition to aspirin for the treatment of unstable angina pectoris: do the results apply to all patients?
Topics: Adult; Aged; Analysis of Variance; Angina, Unstable; Aspirin; Chi-Square Distribution; Cohort Studie | 2000 |
[Therapeutic inhibition of platelets in a acute coronary syndrome and in coronary intervention: mechanisms and clinical results].
Topics: Abciximab; Acute Disease; Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; | 2000 |
[Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Confidence Intervals; Daltepari | 2000 |
[Platelet-leukocyte interactions in coronary heart disease: pathophysiology, clinical relevance, pharmacological modulation].
Topics: Abciximab; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal | 2000 |
Present treatment options for unstable angina and non-Q-wave myocardial infarction.
Topics: Algorithms; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Coro | 2001 |
Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 2000 |
Low-molecular-weight heparin and other antithrombotic agents in the setting of a primarily medical treatment of unstable coronary artery disease.
Topics: Acute Disease; Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as T | 2000 |
Low-molecular-weight heparins in the management of unstable angina.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Combined Modality Therapy; Double-Blind Method; Drug Admi | 2000 |
[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].
Topics: Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Angina, Unstable; Anticoagulants; | 2001 |
Antithrombotic drugs for older subjects. Guidelines formulated jointly by the Italian Societies of Haemostasis and Thrombosis (SISET) and of Gerontology and Geriatrics (SIGG).
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Heparin; Heparin, Low- | 2001 |
Current guidelines for the management of unstable angina: a new diagnostic and management paradigm.
Topics: Adrenergic beta-Antagonists; Algorithms; Angina, Unstable; Anticoagulants; Aspirin; Biomarkers; Coro | 2001 |
Management of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Convertin | 2001 |
Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myo | 2001 |
New approaches to the pharmacological treatment of angina.
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2001 |
Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascula patients?
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; | 2001 |
Unstable angina and non-ST-segment elevation myocardial infarction: perspectives on combination therapy.
Topics: Adenosine Diphosphate; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Dr | 2001 |
From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Heparin; Humans; Intracranial Art | 2002 |
Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Thrombosis; Heparin, Low-Molecular-Weight; Humans; | 2002 |
[Modern therapy in acute coronary syndrome].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Di | 2002 |
Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Care Un | 2002 |
Antiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa antagonist, or all three?
Topics: Administration, Oral; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Costs; | 2002 |
[Acetylsalicylic acid in unstable angina, after coronary revascularization and in prevention of cardiac thromboembolism].
Topics: Angina, Unstable; Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Heart Valve Prosthesis | 1992 |
[Prostaglandins and ischemic cardiopathy].
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Humans; Myocardial Ischemia; Platelet Activation; Pr | 1992 |
[Coronary insufficiency and heparin].
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Heparin; Humans; Myocardi | 1992 |
Aspirin for the prevention of vascular death in women.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Risk | 1992 |
[Angioplasty in unstable angina].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Combined Modali | 1992 |
[Coronary insufficiency and heparin].
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Fibrinolytic Agents; Hepa | 1991 |
Unstable angina: pathophysiology and drug therapy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Calcium Cha | 1990 |
[Drug therapy of acute coronary syndrome. Summary of a hearing arranged by the Norwegian Cardiologic Society and the Institute of pharmacotherapy].
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Aspirin; He | 1990 |
Anti-thrombotic drugs in the treatment of coronary heart disease: the present situation with aspirin.
Topics: Angina, Unstable; Aspirin; Combined Modality Therapy; Coronary Disease; Coronary Thrombosis; Humans; | 1990 |
Pathophysiological role of thromboxane A2 and pharmacological approaches to its inhibition.
Topics: Angina, Unstable; Animals; Aspirin; Humans; Myocardial Infarction; Prostaglandin Endoperoxides, Synt | 1990 |
Unstable angina and thrombolysis.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Coronary Thrombosis; Heparin; Humans; Thrombolytic Thera | 1990 |
Use of desmopressin in the management of aspirin-related and intractable haemorrhage after cardiopulmonary bypass.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Blood Coagulation Tests; Cardiopulmonary Bypass; Deamino Arg | 1990 |
Aspirin and thrombolytic therapy in the management of acute myocardial infarction.
Topics: Angina, Unstable; Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Thrombolytic Therapy | 1990 |
[Aspirin in ischemic heart disease].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation; Po | 1990 |
The Jeremiah Metzger lecture. Participation of eicosanoids in the syndromes of myocardial ischemia.
Topics: Angina, Unstable; Arteriosclerosis; Aspirin; Coronary Disease; Eicosanoids; Humans; Myocardial Infar | 1990 |
Pathophysiology and management of unstable angina.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Aspirin; Electrocardiography; Hepari | 1989 |
Restoration of flow in acute coronary obstructive syndromes: consequences of different management strategies.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Circulation; Humans; | 1989 |
Current perspectives in the antiplatelet therapy of thrombotic disorders.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Humans; | 1989 |
[Platelet antiaggregants and coronary pathology].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Recurrence | 1989 |
Management of unstable angina soon after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon; Anticoagulants | 1988 |
[The state of thrombolytic therapy in acute myocardial infarct].
Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Coronary Artery Bypass; Coronary Vessels; Creatine | 1985 |
Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification.
Topics: Angina, Unstable; Aspirin; Blood Pressure; Cholesterol; Exercise; Heart Diseases; Heart Failure; Hum | 1988 |
Which role for antiplatelet and anticoagulant drugs in unstable angina pectoris?
Topics: Angina, Unstable; Anticoagulants; Aspirin; Humans; Platelet Aggregation Inhibitors | 1988 |
Thrombosis in unstable angina: angiographic aspects.
Topics: Angina Pectoris; Angina, Unstable; Angiography; Arteries; Aspirin; Coronary Circulation; Coronary Di | 1987 |
Clinical trials of antiplatelet drug therapy in acute myocardial infarction, unstable angina, and aortocoronary bypass surgery.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Arte | 1987 |
[Unstable angina pectoris, acute myocardial infarct, sudden heart death. Patho-anatomy and pathophysiology].
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Calcium Channel Blockers; Coronary Angiography; Coronary | 1987 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disea | 1986 |
Effectiveness of anticoagulants.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Blood | 1986 |
Aspirin for the prevention of coronary thrombosis: current facts and perspectives.
Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disea | 1986 |
[Anti-aggregating agents: for which patients?].
Topics: Angina, Unstable; Aspirin; Coronary Artery Bypass; Heart Valve Prosthesis; Humans; Myocardial Infarc | 1986 |
[Controversy on platelet-inhibiting drugs].
Topics: Angina, Unstable; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Cor | 1985 |
153 trials available for aspirin and Angina, Unstable
Article | Year |
---|---|
[The effect of clopidogrel and aspigrel on myocardial ischemia in patients with unstable angina pectoris].
Topics: Aged; Angina, Unstable; Aspirin; Clopidogrel; Drug Combinations; Drug Therapy, Combination; Humans; | 2013 |
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel; | 2016 |
Sulfotanshinone Sodium Injection could decrease fibrinogen level and improve clinical outcomes in patients with unstable angina pectoris.
Topics: Abietanes; Angina, Unstable; Anticoagulants; Aspirin; Dimerization; Drugs, Chinese Herbal; Female; F | 2009 |
5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary
Topics: Abciximab; Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; An | 2010 |
Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting.
Topics: Adenosine Diphosphate; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square D | 2010 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
[Changes in coagulation and fibrinolysis in the patients with coronary heart disease in acute period and effect of drug intervention].
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Coagulation; Case-Control Studies; | 2012 |
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Doub | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Modulation of aspirin-insensitive eicosanoid biosynthesis by 6-methylprednisolone in unstable angina.
Topics: Adult; Angina, Unstable; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Double-Blind Method; E | 2003 |
Early and late effects of clopidogrel in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combinatio | 2003 |
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure | 2003 |
Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets.
Topics: Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cells, Cultured | 2003 |
Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting.
Topics: Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; C | 2003 |
Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Female; Fibrinolytic Agents; Heart Conduction System; Hepari | 2003 |
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin | 2003 |
[Non ST elevation acute coronary syndrome. Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel].
Topics: Acute Disease; Adult; Angina, Unstable; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Dat | 2003 |
Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes.
Topics: Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Double-Blind Method; Eptifibatide; Female; | 2004 |
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Arachidonic Acid; Aspiri | 2004 |
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Topics: Acute Disease; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2004 |
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome.
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypa | 2004 |
Comparison of two strategies for the management of antiplatelet therapy during urgent surgery.
Topics: Aged; Angina, Unstable; Aprotinin; Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Hemostatics | 2005 |
Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biocompatibl | 2005 |
Coronary stent restenosis in patients treated with cilostazol.
Topics: Aged; Angina, Unstable; Aspirin; Cilostazol; Coronary Restenosis; Double-Blind Method; Female; Human | 2005 |
Platelet hyper-function in acute coronary syndromes.
Topics: Administration, Oral; Angina, Unstable; Aspirin; Bleeding Time; Female; Humans; Male; Myocardial Inf | 2005 |
Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Chemistry, Pharmaceutical; Coronary Disease; Female; | 2005 |
Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Follow-U | 2006 |
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin
Topics: Angina, Unstable; Anticoagulants; Aspirin; Enoxaparin; Eptifibatide; Female; Heparin; Humans; Male; | 2006 |
Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Adult; Aged; Angina, Unstable; Aspirin; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination; | 2006 |
Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; C-Reactive Protein; CD40 Ligand; Clopidogrel; Dose-R | 2006 |
Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients.
Topics: Aged; Angina, Unstable; Aspirin; Bleeding Time; Blood Viscosity; Clopidogrel; Drug Resistance; Eryth | 2006 |
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; | 2006 |
The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Follow-Up | 2006 |
Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Biomarkers; Cardiac Catheterization; C | 2007 |
Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy).
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Corona | 2007 |
Effects of Quyu xiaoban capsules on clinical outcomes and platelet activation and aggregation in patients with unstable angina pectoris.
Topics: Angina, Unstable; Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Comb | 2007 |
Effects of Quyu Xiaoban capsules on clinical outcomes and platelet activation and aggregation in patients with unstable angina pectoris.
Topics: Adult; Angina, Unstable; Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therap | 2007 |
Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Cardiovascular Agents; Evidence-Based Medicine; | 2007 |
Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Female; Hirudin Therapy; Hirudins; Humans; Male; Mid | 2007 |
Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Canada; Cl | 2007 |
[Unstable angina: efficacy and tolerability of therapy with aspirin and aspirin combined with ticlopidine].
Topics: Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progression; Drug Therap | 2007 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com | 2008 |
Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clinical Trials as Topic; Death, Sudden; Dou | 1983 |
Mechanisms contributing to precipitation of unstable angina and acute myocardial infarction: implications regarding therapy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon; Animals; Antic | 1984 |
The diagnostic and prognostic importance of ambulatory ST recording compared to a predischarge exercise test after an episode of unstable angina or non-Q wave myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Angina, Unstable; Aspirin; Coronary Disease; Dos | 1995 |
Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Drug Therapy, Combination; Female; | 1995 |
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Angiography; Dose-Response Relationship, Drug; Doub | 1995 |
Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group.
Topics: Angina, Unstable; Aspirin; Female; Heparin; Humans; Infusions, Intravenous; Injections, Subcutaneous | 1995 |
Heparin and aspirin in unstable angina: insufficient sample size may lead to erroneous conclusions.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Heparin; Humans; Myocardial Ischemia; Sample S | 1995 |
[Adverse effects of combined use of acenocoumarol and acetylsalicylic acid after myocardial infarct and unstable angina].
Topics: Acenocoumarol; Angina, Unstable; Aspirin; Drug Synergism; Drug Therapy, Combination; Female; Hemorrh | 1995 |
Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Calcium Channel Blockers; Drug Therapy | 1993 |
[Unstable angina: effect of aspirin and heparin on treatment outcome in hospital patients (a double-blind, placebo-controlled study)].
Topics: Administration, Oral; Adult; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Female; Follow-Up | 1993 |
[Ticlopidine and aspirin in the treatment of unstable angina: comparative evaluation of their effect of anti-aggregation and platelet membranes].
Topics: Adult; Aged; Angina, Unstable; Anti-Arrhythmia Agents; Aspirin; Cholesterol; Heparin; Humans; Male; | 1993 |
Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. The Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
Topics: Adult; Angina, Unstable; Aspirin; Delayed-Action Preparations; Drug Therapy, Combination; Epoprosten | 1994 |
Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Diltiazem; Drug Therapy, Combinatio | 1994 |
Aspirin versus heparin in the acute phase of unstable angina.
Topics: Angina, Unstable; Aspirin; Heparin; Humans; Linear Models; Logistic Models; Myocardial Infarction | 1994 |
[Unstable angina: tissue-type plasminogen activator inhibitor and other hemostatic factors in aspirin and intravenous heparin administration].
Topics: Administration, Oral; Angina, Unstable; Aspirin; Double-Blind Method; Female; Hemostasis; Heparin; H | 1993 |
The role of extraplatelet thromboxane A2 in unstable angina investigated with a dual thromboxane A2 inhibitor: importance of activated monocytes.
Topics: Aged; Angina Pectoris; Angina, Unstable; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hu | 1994 |
Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.
Topics: Acute Disease; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Factor Ana | 1993 |
Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agen | 1994 |
Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Coronary Disease; Electrocardiography; Exercise Test; Hemodynamics; | 1993 |
Antiplatelet therapy--Part I.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronar | 1993 |
[Diltiazem versus intravenous nitroglycerin in the treatment of unstable angina pectoris. A randomized study].
Topics: Aged; Analysis of Variance; Angina, Unstable; Anticoagulants; Aspirin; Blood Pressure; Cardiovascula | 1995 |
Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Daltepa | 1996 |
Early continuous ST segment monitoring in unstable angina: prognostic value additional to the clinical characteristics and the admission electrocardiogram.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Aspirin; Electrocardiography; Electrocar | 1996 |
Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3).
Topics: Abciximab; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; As | 1995 |
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Bleeding Time; Dose-Respo | 1996 |
Refining the treatment of women with unstable angina--a randomized, double-blind, comparative safety and efficacy evaluation of Integrelin versus aspirin in the management of unstable angina.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Double-Blind Method; Electrocardiography, Ambula | 1996 |
Comparison of heparin therapy for < or = 48 hours to > 48 hours in unstable angina pectoris.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Coronary Angi | 1997 |
Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial).
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Hemorrhage; Heparin; Humans; Plasminogen Activators | 1997 |
Pathophysiology of transient myocardial ischemia in acute coronary syndromes. Characterization by continuous ST-segment monitoring.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Circadian Rhythm; Drug Therapy, Combinatio | 1997 |
[Secondary prevention in chronic coronary heart disease].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angiotensin-Convertin | 1997 |
Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Blood Coagulation Tests; | 1997 |
First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions.
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Benzamidines; Coronary Arter | 1997 |
Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Angiography; Coronary Vessels; Double-Blind Meth | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina.
Topics: Aged; Angina, Unstable; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy | 1997 |
Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Double-Blind | 1997 |
[Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coro | 1997 |
[Clinical safety using the thrombocyte aggregation inhibitor c7E3 in interventional cardiology in 520 patients].
Topics: Abciximab; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Angina, Unstable | 1997 |
Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Aspirin; Calcium Channel Blockers; Elect | 1998 |
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolyti | 1998 |
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolyti | 1998 |
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Gl
Topics: Acetates; Aged; Angina, Unstable; Anticoagulants; Aspirin; Female; Hemorrhage; Heparin; Humans; Male | 1998 |
Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspi | 1998 |
Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results.
Topics: Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombin | 1998 |
Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
[Antithrombotic agents in unstable angina. Review of clinical trials].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hirudin | 1998 |
[Effectiveness of unstable angina pectoris treatment by aggregation inhibitors ticlid and aspirin].
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Electrocardiography, Ambulatory; Female; | 1998 |
Effects of aprotinin during cardiopulmonary bypass in patients treated with acetylsalicylic acid.
Topics: Adenosine Triphosphate; Adult; Aged; Angina, Unstable; Aprotinin; Aspirin; Blood Loss, Surgical; Blo | 1998 |
Attenuated severity of new acute ischemic events in patients with previous coronary heart disease receiving long-acting nitrates.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Calcium Channel Blo | 1999 |
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Electrocardiography; Eptifibatide; Female; Follow-Up | 1999 |
Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators.
Topics: Aged; Angina, Unstable; Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation I | 1999 |
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Topics: Acute Disease; Age Factors; Aged; Angina, Unstable; Aspirin; Brain Damage, Chronic; Cerebral Hemorrh | 1999 |
Coronary artery flow ten weeks after myocardial infarction or unstable angina: effects of combined warfarin and aspirin therapy.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Flow Velocity; Coronary Angiography; Coronary Circu | 1999 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti | 1999 |
Randomized clinical trial of urokinase versus heparin in unstable angina.
Topics: Adult; Aged; Angina, Unstable; Aspirin; China; Dose-Response Relationship, Drug; Drug Therapy, Combi | 1999 |
Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
Topics: Adult; Angina, Unstable; Anticoagulants; Aspirin; Death, Sudden, Cardiac; Double-Blind Method; Drug | 1999 |
The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study: evaluation of acute and long-term therapies for patients with acute coronary syndromes without ST elevation.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Aspirin; Canada; Death, Sudden, Cardiac; Dose | 1999 |
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coron
Topics: Administration, Oral; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Female; Humans; Male; Mi | 2000 |
Long-term management--the way forward?
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Dalteparin; Drug Therapy, Combin | 2000 |
Antithrombotic effects of abciximab.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Aspirin; Drug Therapy, Combination; Fibrinolyti | 2000 |
Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.
Topics: Aged; Angina, Unstable; Aspirin; Drug Administration Routes; Drug Therapy, Combination; Electrocardi | 2000 |
Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.
Topics: Aged; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Biomarkers; Blood Platelets; Daltepa | 2000 |
Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina.
Topics: Angina, Unstable; Antioxidants; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprost; Dose-Respons | 2000 |
[Clinical effectiveness and specific action of antiaggregants in patients with unstable angina].
Topics: Angina, Unstable; Aspirin; Electrocardiography, Ambulatory; Female; Hemostasis; Humans; Male; Middle | 2000 |
Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Uns
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Diabetes Complications; Disease Progression; Double | 2000 |
Effect of aspirin and ticlopidine on plasma tissue factor levels in stable and unstable angina pectoris.
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombin III; Aspirin; Athere | 2000 |
The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Humans; Meta-Analysis as Topic; Platelet Aggregation Inhibit | 2000 |
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Biphenyl Compounds; Double-Blind Method; Female; He | 2000 |
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators.
Topics: Administration, Oral; Adult; Aged; Angina, Unstable; Anticoagulants; Aspirin; Dose-Response Relation | 2001 |
Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Double-Blind Method; Enoxaparin; Female; Heparin; Humans; | 2001 |
Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Monophosphate; Adult; Aged; Angina, Unstable; Aspirin; Blood Coagulation Te | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2001 |
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
Topics: Aged; Alanine; Angina, Unstable; Antigens, Human Platelet; Aspirin; Double-Blind Method; Female; Gen | 2001 |
[Effect of Composite Salviae Dropping Pill on function of platelet activation in patients with unstable angina pectoris].
Topics: Adult; Aged; Angina, Unstable; Aspirin; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hu | 2000 |
Insights from CURE: using clopidogrel on top of standard therapy.
Topics: Aged; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Hepari | 2002 |
[Comparative efficacy of tiklid and aspirin in patients with unstable angina].
Topics: Angina, Unstable; Aspirin; Blood Coagulation; Endothelium, Vascular; Female; Fibrinolytic Agents; Hu | 2001 |
Prognostic significance of elevated troponin I after percutaneous coronary intervention.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Creatine Kinase; Creatine Kin | 2002 |
Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study.
Topics: Acute Disease; Adult; Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coro | 2002 |
Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure.
Topics: Adult; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers; Coronary | 1992 |
Randomized trial of thrombolysis versus heparin in unstable angina.
Topics: Angina, Unstable; Aspirin; Female; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Infarct | 1992 |
Diagnostic and prognostic importance of ST recording after an episode of unstable angina or non-Q-wave myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Angina, Unstable; Aspirin; Coronary Care Units; Double-Blind Meth | 1992 |
Reactivation of unstable angina after the discontinuation of heparin.
Topics: Acute Disease; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; He | 1992 |
Thrombolytic therapy in refractory unstable angina: the role of Holter monitoring.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Calcium Channel Blockers; Electrocardiograph | 1991 |
Should the exercise test (ET) be performed at discharge or one month later after an episode of unstable angina or non-Q-wave myocardial infarction?
Topics: Angina, Unstable; Aspirin; Double-Blind Method; Electrocardiography; Exercise Test; Follow-Up Studie | 1991 |
Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in
Topics: Administration, Oral; Angina, Unstable; Aspirin; Coronary Angiography; Electrocardiography; Follow-U | 1991 |
Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina.
Topics: Administration, Oral; Aged; Analysis of Variance; Angina Pectoris; Angina, Unstable; Aspirin; Double | 1990 |
Ticlopidine in unstable angina. A more expensive aspirin?
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Cost-Benefit Analysis; Cycloox | 1990 |
Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angiography; Aspirin; Cardiac Catheterization; Coronary Ang | 1990 |
Long-term maintenance of thromboxane inhibition by two different aspirin regimens in patients with unstable angina.
Topics: Angina, Unstable; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Dose-Response Relationship, D | 1990 |
[Anticoagulantion and antiaggregation therapy in patients with unstableangina pectoris].
Topics: Angina, Unstable; Aspirin; Dipyridamole; Drug Therapy, Combination; Electrocardiography; Female; Hep | 1990 |
Ticlopidine in unstable angina.
Topics: Angina, Unstable; Aspirin; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 1990 |
Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina.
Topics: Adolescent; Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coron | 1990 |
Unstable angina or non-Q wave infarction despite long-term aspirin: response to thrombolytic therapy with implications on mechanisms.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angiography; Aspirin; Biomechanical Phenomena; Cerebral Hem | 1990 |
Comparison of low-dose aspirin and coronary vasodilators in acute unstable angina.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Diltiazem; Drug Therapy, Combination; Electrocardiograph | 1990 |
Restoration of flow in acute coronary obstructive syndromes: consequences of different management strategies.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Circulation; Humans; | 1989 |
Comparative study of heparin and antiplatelets in treatment of preinfarction angina.
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Dipyridamole; Dru | 1989 |
Current perspectives in the antiplatelet therapy of thrombotic disorders.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Humans; | 1989 |
Aspirin for prevention of myocardial infarction and stroke.
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Ischemic Att | 1989 |
[Do thrombocyte aggregation inhibitors modify silent episodes of unstable angina pectoris in combined anti-angina therapy?].
Topics: Aged; Angina Pectoris; Angina, Unstable; Aspirin; Coronary Circulation; Diltiazem; Drug Therapy, Com | 1989 |
Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave myocardial infarction.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Coronary Angiography; Drug Therapy, Combination; Electro | 1989 |
Prevention of coronary heart disease in practice. Implications of the results of recent clinical trials.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Aspirin; Blood Platelets; Cholesterol; C | 1985 |
Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angiography; Aspirin; Clinical Trial | 1987 |
Aspirin, heparin, or both to treat acute unstable angina.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Double-Blind Me | 1988 |
Clinical trials of antiplatelet drug therapy in acute myocardial infarction, unstable angina, and aortocoronary bypass surgery.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Arte | 1987 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disea | 1986 |
Aspirin to prevent myocardial infarction and death.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Myocardi | 1986 |
Effectiveness of anticoagulants.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Blood | 1986 |
Aspirin for the prevention of coronary thrombosis: current facts and perspectives.
Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disea | 1986 |
[Controversy on platelet-inhibiting drugs].
Topics: Angina, Unstable; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Cor | 1985 |
Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Double-Blind Method; Drug Ther | 1985 |
Unstable angina: status of aspirin and other forms of therapy.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Double | 1985 |
202 other studies available for aspirin and Angina, Unstable
Article | Year |
---|---|
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithro | 2020 |
Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PCI patients.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial Infa | 2020 |
Acute coronary syndromes: summary of updated NICE guidance.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Cardiac Rehabilitation; Clopidogrel; Combined Mo | 2021 |
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabete | 2021 |
Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Beijing; Clopidogrel; Databases, Factual; Diabet | 2021 |
Pragmatic approach to chest pain patients discharged with undetectable high-sensitivity troponin T and normal electrocardiogram: the STABS + CT protocol.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Biomarkers; Chest Pain; Computed Tomog | 2017 |
[Focused update on dual antiplatelet treatment : ESC guidelines 2017].
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com | 2017 |
[Platelet inhibition in elderly patients].
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Humans; Percutaneous Coronary Intervention | 2018 |
Long-term follow-up of antithrombotic management patterns in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticoagulants; Aspirin; Female; Follow-Up Studies; Human | 2018 |
[Special characteristics of progression of myocardial remodeling in patients with various forms of unstable angina].
Topics: Aged; Angina, Unstable; Aspirin; Benzopyrans; Cardiovascular Agents; Disease Progression; Drug Thera | 2014 |
T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients.
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Aspirin; Atrial Natriuretic Factor; Female | 2016 |
[Two catheters for one coronary perforation].
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Cardiac Ca | 2015 |
Use of Health Care System-Supplied Aspirin by Veterans With Postoperative Heart Attack or Unstable Angina.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiology; Evidence-Based | 2015 |
Management of acute coronary syndromes in a developing country; time for a paradigm shift? an observational study.
Topics: Acute Coronary Syndrome; Aged; Alcoholism; Angina, Unstable; Aspirin; Delayed Diagnosis; Developing | 2015 |
Pre-hospital management of acute coronary syndrome patients in Belgium and Luxembourg and other Western European countries.
Topics: Acute Coronary Syndrome; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Belgium | 2016 |
Searching the right coronary artery we found a rare anomaly documented by 3-dimensional volume rendering.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Computed Tomography Angiography; Conservativ | 2016 |
Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy | 2016 |
[Acute coronary syndrome -- long term protection by dual thrombocyte aggregation inhibition during twelve months].
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials | 2008 |
Responsiveness to aspirin in patients with unstable angina pectoris by whole blood aggregometry.
Topics: Aged; Angina, Unstable; Aspirin; Drug Resistance; Electric Impedance; Female; Humans; Male; Middle A | 2009 |
Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Clopido | 2009 |
Combined carotid stenting and urgent coronary artery surgery in unstable angina patients with severe carotid stenosis.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon; Anticoagulants; Aspirin; Carotid St | 2009 |
The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Comorbidity; Drug Resistance; Electrocardi | 2009 |
Weighing benefits and risks--the FDA's review of prasugrel.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Causality; Clini | 2009 |
Temporal trends in patient-reported angina at 1 year after percutaneous coronary revascularization in the stent era: a report from the National Heart, Lung, and Blood Institute-sponsored 1997-2006 dynamic registry.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; An | 2009 |
Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression.
Topics: Adenosine Diphosphate; Aged; Angina, Unstable; Anxiety Disorders; Aspirin; Clopidogrel; Cross-Sectio | 2010 |
Hemorrhagic cholecystitis after anticoagulation therapy.
Topics: Adenocarcinoma; Aged; Angina, Unstable; Anticoagulants; Aspirin; Cholecystitis; Female; Gallbladder | 2010 |
[Registries of myocardial infarction in Germany. Consequences for drug therapy of patients with acute ST elevation myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Corona | 2010 |
Aspirin desensitization/challenge in 3 patients with unstable angina.
Topics: Angina, Unstable; Aspirin; Desensitization, Immunologic; Humans; Male; Middle Aged; Platelet Aggrega | 2010 |
Dosing of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clop | 2010 |
Differences in the mode of presentation for acute coronary syndrome by pre-hospitalization medication, in relation to coronary risk factors, East-Osaka acute coronary syndrome (EACS) registry.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Coronary Arte | 2011 |
Aneurysm formation after drug-eluting balloon treatment of drug-eluting in-stent restenosis: first case report.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheters; Cardiovascular Agents; | 2012 |
Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Clopidogrel; Computer Simulation; Cost-Ben | 2012 |
Follow-up of aspirin-resistant patients with end-stage kidney disease.
Topics: Aged; Angina, Unstable; Area Under Curve; Aspirin; Cause of Death; Cohort Studies; Drug Resistance; | 2013 |
[New US guidelines. Myocardial infarct is now treated more aggressively].
Topics: Angina, Unstable; Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Humans; Myoc | 2002 |
Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE).
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Australia; Canada; E | 2002 |
[Role of emergency departments in acute myocardial infarction care. EVICURE study].
Topics: Aged; Angina, Unstable; Aspirin; Coronary Care Units; Diagnosis, Differential; Emergency Service, Ho | 2002 |
Clopidogrel plus aspirin for stroke prevention.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Follow- | 2002 |
A partial CURE for acute coronary syndromes--but how did it happen?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platele | 2002 |
Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cor | 2002 |
New treatment guidelines for unstable angina/non-ST-segment elevation myocardial infartion.
Topics: Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Heparin, Low-Molecu | 2002 |
[New guidelines in acute coronary syndrome. Clopidogrel for nine months is recommended].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hum | 2002 |
[Baseline characteristics and management of patients less than 45 years of age hospitalized for acute coronary syndromes: results from the nationwide French PREVENIR 1 and PREVENIR 2 studies].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Angina, Unstable; Angiotensin-Converting Enzyme Inh | 2002 |
[Prospective analysis of conservative treatment of acute coronary syndrome].
Topics: Acute Disease; Adult; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cor | 2002 |
Unstable angina and non-Q-wave myocardial infarction. Treatment beyond aspirin and heparin.
Topics: Angina, Unstable; Aspirin; Electrocardiography; Fibrinolytic Agents; Heparin; Humans; Myocardial Inf | 1999 |
[In acute coronary syndrome. Seize platelets with pliers].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2002 |
Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Case-Control S | 2002 |
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Creatinine; Drug Monitoring; Eno | 2003 |
Pharmacological treatment of acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clopidogrel; Humans; Myocardial Infarction; | 2003 |
Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Coagulation Tests; C | 2003 |
[Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prevenir 1, Prevenir 2 and Usic 2000 surveys].
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme In | 2003 |
Long-term prognosis of patients with acute coronary syndrome and moderate coronary artery stenosis.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Coronary Angiography; C | 2003 |
Usefulness of an acute coronary syndrome pathway to improve adherence to secondary prevention guidelines.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Aspir | 2003 |
[Acute coronary syndrome. The second platelet inhibitor is self-paid].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analys | 2003 |
The central role of platelet activation in determining the severity of acute coronary syndromes.
Topics: Angina, Unstable; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activa | 2003 |
[Dual platelet inhibition with clopidogrel and ASS. Who profits from the combination?].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2003 |
Antiplatelet therapy for ischemic heart disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid | 2004 |
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Comorbid | 2004 |
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2004 |
[Recommendations for cardiovascular rehabilitation in diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon; Aspirin; Blood Glucose; Cardiov | 2003 |
[Experience with the use of autoarterial conduits in coronary surgery].
Topics: Anastomosis, Surgical; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; A | 2004 |
Long-term management of patients with unstable angina and non-ST-elevation MI.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA R | 2004 |
Building evidence for early initiation of clopidogrel loading in non-ST-segment elevation acute coronary syndromes: going past the American College of Cardiology/American Heart Association guidelines.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; E | 2004 |
[Combination is standard. Dual thrombocyte function inhibition in acute coronary syndrome].
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; | 2004 |
[Interview with Prof. Dr. H. J. Rupprecht about secondary prevention: what is the optimal thrombocyte function inhibition?].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Long-Term Care; Myocardia | 2004 |
Severe stenosis of anastomoses by using the symmetry aortic connector system.
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Arter | 2004 |
[Use of assessment of aggregation of thrombocytes induced by cationic propyl gallate to estimate recurrence of cardiovascular complications].
Topics: Adult; Aged; Angina, Unstable; Aspirin; Drug Resistance; Female; Humans; Male; Myocardial Infarction | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Gender differences in therapy for patients admitted for unstable angina and myocardial infarction with underlying chronic kidney disease.
Topics: Acute Disease; Aged; Aged, 80 and over; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; | 2004 |
Long-term combination therapy with aspirin and clopidogrel.
Topics: Angina, Unstable; Arteriosclerosis; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Double-Blind Me | 2004 |
Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone?
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry.
Topics: Adolescent; Adult; Aged; Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; | 2005 |
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; | 2004 |
An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease.
Topics: Abciximab; Adult; Aged; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Aspirin; C-Reactiv | 2005 |
Medication performance measures and mortality following acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhi | 2005 |
Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting.
Topics: Abciximab; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Mono | 2005 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy | 2005 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy | 2005 |
Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anemia; Angina, Unstable; Angiotensin-Converting Enzyme In | 2005 |
Potent low dose platelet inhibitory effects of clopidogrel and aspirin on coronary thrombus formation in an animal model of acute unstable angina.
Topics: Acute Disease; Angina, Unstable; Animals; Aspirin; Clopidogrel; Coronary Thrombosis; Disease Models, | 2006 |
Embedded guideline information without patient specificity in a commercial emergency department computerized order-entry system.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clopidogrel; Decision Support Systems, Clini | 2006 |
Delay in the diagnosis of acute myocardial infarction: effect on quality of care and its assessment.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; C | 2006 |
[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome].
Topics: Age Factors; Aged; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Com | 2006 |
Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Arteries; Aspirin; beta-Thromboglobulin; Blood Pla | 2006 |
Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes.
Topics: Aged; Angina, Unstable; Aspirin; Depression; Female; Humans; Male; Middle Aged; Myocardial Infarctio | 2006 |
Non-ST-elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Cardiac Catheterization; Coronary Angiograph | 2007 |
Self-reported use of complementary and alternative medicine in patients with previous acute coronary syndrome.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angina, Unstable; Aspirin; Complementary Th | 2007 |
Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative.
Topics: Acute Disease; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Dise | 2007 |
Aspirin is lifesaving for cancer patients with ACS. Benefits of aspirin treatment for patients with acute coronary syndrome are immediate.
Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Neoplasms; Platelet Aggregation Inhibitors | 2007 |
[Soluble CD40 ligand: a potential marker of cardiovascular risk].
Topics: Abciximab; Acute Coronary Syndrome; Alanine; Angina, Unstable; Animals; Antibodies, Monoclonal; Anti | 2007 |
Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; A | 2007 |
Guideline-based discharge therapy for unstable angina pectoris/non-ST elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Electrocardiography; Humans; Hypolipidemic Agents; Myocardia | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk.
Topics: Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Car | 2007 |
The truth and consequences of the COURAGE trial.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Ang | 2007 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
[Efficacy of intravenous aspirin use in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Administration, Oral; Adult; Aged; Aged, 80 and over; Angina, Unstable; Asp | 2007 |
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin; | 2008 |
Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Coronary Disease; Disease-Free Survival; Female; | 2008 |
Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database.
Topics: Acute Coronary Syndrome; Adult; Age Distribution; Aged; Aged, 80 and over; Angina, Unstable; Aspirin | 2008 |
Unstable angina in a patient with mucocutaneous lymph node syndrome.
Topics: Aneurysm; Angina Pectoris; Angina, Unstable; Aspirin; Child; Coronary Angiography; Coronary Artery B | 1984 |
Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms.
Topics: Adult; Aged; Angina Pectoris; Angina Pectoris, Variant; Angina, Unstable; Aorta; Aspirin; Blood Pres | 1984 |
Treating unstable angina.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Female; Heparin; Humans; Injections, Intravenous; Injections | 1995 |
Heparin in unstable angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Female; Heparin; Humans; Infusions, Intravenou | 1995 |
Heparin in unstable angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Female; Heparin; Humans; Infusions, Intravenou | 1995 |
Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes.
Topics: Angina, Unstable; Aspirin; Case-Control Studies; Chest Pain; Electrocardiography; Female; Humans; Ma | 1995 |
Increased number of thromboxane A2-prostaglandin H2 platelet receptors in active unstable angina and causative role of enhanced thrombin formation.
Topics: Aged; Angina Pectoris; Angina, Unstable; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; | 1995 |
Management of cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia using prostaglandin E1 and aspirin.
Topics: Aged; Alprostadil; Angina, Unstable; Aspirin; Cardiopulmonary Bypass; Coronary Artery Bypass; Female | 1994 |
Plasma lipoprotein(a) levels and fibrinolytic activity in patients with unstable angina.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Calcium Chan | 1993 |
[Sliding indications for balloon angioplasty].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspi | 1994 |
Antithrombin-III plasma activity during and after prolonged use of heparin in unstable angina.
Topics: Angina, Unstable; Antithrombin III; Antithrombin III Deficiency; Aspirin; Female; Heparin; Humans; M | 1993 |
Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Antithrombin III; Aspirin; Blood Coagulation; Female; Hum | 1993 |
Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Female; Flow Cytometry; Glutathione; Huma | 1996 |
Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction.
Topics: Aged; Angina, Unstable; Aspirin; Gastrointestinal Hemorrhage; Hemoglobins; Humans; Middle Aged; Myoc | 1996 |
[Current point of view on medical treatment of unstable angina].
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin | 1996 |
Benefit of heparin plus aspirin vs aspirin alone in unstable angina.
Topics: Angina, Unstable; Aspirin; Heparin; Humans; Meta-Analysis as Topic; Myocardial Infarction | 1996 |
Benefit of heparin plus aspirin vs aspirin alone in unstable angina.
Topics: Angina, Unstable; Aspirin; Hemorrhage; Heparin; Humans; Myocardial Infarction | 1996 |
Benefit of heparin plus aspirin vs aspirin alone in unstable angina.
Topics: Angina, Unstable; Aspirin; Hemorrhage; Heparin; Humans; Myocardial Infarction | 1996 |
[Medical treatment of acute coronary syndrome].
Topics: Acute Disease; Angina, Unstable; Aspirin; Coronary Disease; Fibrinolytic Agents; Heparin; Humans; Pl | 1995 |
Increasing the stability of unstable angina.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Drug Therapy, Combination; Humans; Treatment | 1997 |
Unstable coronary artery disease--need for long-term antithrombotic treatment. Aspirin alone is not sufficient, I would associate an anticoagulant.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination; Humans; Plat | 1997 |
Outcome of unstable angina in patients with diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angioplasty; Aspirin; Calcium Channel Blockers; | 1997 |
Unstable angina: integrating new treatments.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Aspirin; Contraindications; Drug Therapy, Combi | 1997 |
[Low-dose ASA and infarct prophylaxis. Acetylsalicylic acid (ASA): low doses with high efficiency].
Topics: Angina, Unstable; Aspirin; Dose-Response Relationship, Drug; Humans; Myocardial Infarction | 1995 |
Early aggressive treatment of unstable angina without on-site cardiac surgical facilities: a prospective study of acute and long-term outcome.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, | 1998 |
Aspirin for prevention of myocardial infarction. A double-edged sword.
Topics: Aged; Aged, 80 and over; Anemia; Angina, Unstable; Aspirin; Female; Gastrointestinal Hemorrhage; Hum | 1997 |
Trends in the quality of care for Medicare beneficiaries admitted to the hospital with unstable angina.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Connecticut; Female; Guideline A | 1998 |
Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardi | 1998 |
[Effects of different lowdoses of aspirin on platelet activation and the number of platelets in the patients with coronary heart disease].
Topics: Aged; Angina, Unstable; Aspirin; Female; Humans; Male; Middle Aged; P-Selectin; Platelet Aggregation | 1996 |
Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Cardiac Catheterization; Cohort Studie | 1998 |
Tirofiban in unstable coronary disease.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardi | 1998 |
Low molecular weight heparins in acute ischaemic syndromes.
Topics: Angina, Unstable; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; | 1998 |
New antiplatelet agents.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid | 1998 |
Coronary stenting in unstable angina: early and late clinical outcomes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coronary Disease; | 1998 |
Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina.
Topics: Aged; Angina, Unstable; Anticoagulants; Antithrombin III; Aspirin; Biomarkers; Female; Fibrinopeptid | 1998 |
Eptifibatide in acute coronary syndromes.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Eptifibatide; Heparin; Humans; Myocardial Infarction; Pep | 1999 |
Super-aspirins in severe angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Eptifibatide; Fibrinolytic Agents; Heparin; Hu | 1998 |
Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY)
Topics: Angina, Unstable; Aspirin; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Myocard | 1999 |
Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Drug Therapy, Combination; Electrocard | 1999 |
Trends in the post-hospitalization medical treatment of unstable angina pectoris: 1990 to 1995.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Calcium Channel Blockers; Cohort Studi | 1999 |
Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Enoxaparin; Humans; Myocardial Infarction; Tr | 1999 |
[The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis].
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Coronary Disease; Drug Resistance; Female; Hospitali | 1999 |
Clinical practice guidelines in unstable angina improve clinical outcomes by assuring early intensive medical treatment.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspiri | 1999 |
Low molecular weight heparins in acute coronary syndrome.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Double-Blind Method; Enoxapari | 2000 |
Introduction: Expanding the horizons in unstable coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Coronary Thrombosis; Disease Man | 2000 |
Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Anticholesteremic Agents; Aspirin; Clinical Trials as | 2000 |
Long-term outcome in patients treated by intracoronary stenting with ticlopidine and aspirin, and deleterious prognostic role of unstable angina pectoris.
Topics: Aged; Angina, Unstable; Aspirin; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; | 2000 |
[Unstable angina pectoris: preventing the infarct. Thrombosis ABC, 14].
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Heparin; Heparin, Low-Molecular-Weight; Humans; Prog | 2000 |
Unstable angina pectoris.
Topics: Angina, Unstable; Aspirin; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2000 |
Heparin should be administered to every patient admitted to the hospital with possible unstable angina.
Topics: Angina, Unstable; Aspirin; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myoc | 2000 |
Drip and ship: a new strategy for the treatment of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; | 2000 |
Increased rate of formation of small-sized platelet aggregates in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Cohort Studies; Coronary D | 2000 |
Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
Topics: Angina, Unstable; Angioplasty; Anticoagulants; Aspirin; Cardiovascular Diseases; Clinical Trials as | 2000 |
Randomisation in the SYMPHONY trial.
Topics: Angina, Unstable; Aspirin; Double-Blind Method; Humans; Oximes; Piperidines; Platelet Aggregation In | 2000 |
[Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; | 2000 |
How hot is inflammation in acute coronary syndrome?
Topics: Angina, Unstable; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Corona | 2000 |
The effect of aspirin on C-reactive protein as a marker of risk in unstable angina.
Topics: Aged; Angina, Unstable; Aspirin; Biomarkers; C-Reactive Protein; Cohort Studies; Female; Follow-Up S | 2001 |
Platelet aggregability under shear is enhanced in patients with unstable angina pectoris who developed acute myocardial infarction.
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Biomarkers; Comorbidity; Coronary Thrombosis; Creat | 2001 |
A study of the use of aspirin by general practitioners in suspected myocardial infarction.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chest Pain; Data Collection; Drug Utilization; Family Practi | 2001 |
[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clinical Trials as Topic; | 2001 |
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibod | 2001 |
[Which medical treatment can minimize late complications after pharmacologic treatment of unstable angina?].
Topics: Adrenergic beta-Antagonists; Ambulatory Care; Angina, Unstable; Angiotensin-Converting Enzyme Inhibi | 2000 |
Quality of care among elderly patients hospitalized with unstable angina.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Connecticut; Electrocardiography | 2001 |
Clopidogrel in invasive management of non-ST-elevation ACS.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Humans; My | 2001 |
[Antithrombotic therapy of unstable angina pectoris].
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardi | 1998 |
[Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hu | 2001 |
Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Angioplasty, | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Fibrinolytic A | 2001 |
Guideline-compliant care improves one-year outcomes in patients with unstable angina.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Coronary Artery Bypass; Heart Failure; | 2000 |
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
Topics: Age Factors; Aged; Angina, Unstable; Area Under Curve; Aspirin; Biomarkers; Body Weight; Coronary Ar | 2002 |
Early statin initiation and outcomes in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Reductase | 2002 |
[Development of myocardial infarction in aspirin-treated unstable angina pectoris. Repeated studies of platelet aggregation and of the thromboxane-prostacyclin system].
Topics: Adult; Angina, Unstable; Aspirin; Epoprostenol; Humans; Male; Middle Aged; Myocardial Infarction; Pl | 1992 |
Predischarge exercise echocardiography in patients with unstable angina who respond to medical treatment.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Aspirin; Calcium Channel Blockers; Cardi | 1992 |
Effect of maximal medical therapy on refractoriness of unstable angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Calciu | 1992 |
Is thrombolytic therapy striking out in unstable angina?
Topics: Angina, Unstable; Aspirin; Heparin; Humans; Myocardial Infarction; Thrombolytic Therapy; Urokinase-T | 1992 |
Thrombosis in unstable angina.
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Heparin; Humans; Myocardial Infarction; Prognosis; T | 1992 |
Low-dose aspirin and heparin in unstable coronary artery disease.
Topics: Angina, Unstable; Aspirin; Heparin; Humans; Time Factors | 1991 |
[Heparin therapy in coronary disease].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Drug Therapy, Combination; Heparin; Humans; Myocardial | 1992 |
Use of acetylsalicylic acid by physicians and in the community.
Topics: Adolescent; Adult; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Community Medicine; Dru | 1991 |
Clinical and angiographic characteristics and outcome of patients with rest-unstable angina occurring during regular aspirin use.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Coronary Angiography; Female; Follo | 1991 |
Coronary angioplasty for medically refractory unstable angina in patients with prior coronary bypass surgery.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary | 1990 |
[Treatment of unstable angina pectoris. A questionnaire study].
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Calcium Channel Blockers; Denmark; Drug Util | 1990 |
[Drug therapy of unstable angina].
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Calcium Channel Blockers; Drug Therapy, Comb | 1990 |
Therapeutic interventions which may improve survival in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Aspirin; Coronary Artery Bypass; Cor | 1990 |
[Adhesive activity of blood platelets in patients with stable or unstable angina pectoris and acute myocardial infarct].
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Aspirin; Creatine Kinase; Humans; Male; Microscopy, | 1991 |
Detection of silent myocardial ischemia in asymptomatic selected population and in unstable angina.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Disease; Electrocardiography, Ambulatory; Exercise | 1990 |
Product licences and devious promotion.
Topics: Advertising; Angina, Unstable; Aspirin; Drug Industry; Myocardial Infarction; United Kingdom | 1990 |
[Aspirin in the prevention and management of coronary artery disease].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Humans; Myocardial Infarction | 1990 |
Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina.
Topics: Aged; Angina Pectoris; Angina, Unstable; Aspirin; Bleeding Time; Blood Platelets; Chest Pain; Epinep | 1990 |
[Unstable stenocardia: various problems of pathogenesis and treatment].
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Constriction, Pathologic | 1989 |
Aspirin, heparin, or both to treat unstable angina.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Heparin; Humans; Myocardial Infarction | 1989 |
Unstable angina revisited once more.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon; Aspirin; Combi | 1986 |
Management of patients after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Cardiac Cat | 1987 |
Use of percutaneous transluminal coronary angioplasty and bypass surgery despite improved medical therapy for unstable angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon; Aspirin; Calci | 1988 |
Coronary angioplasty in refractory unstable angina.
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon; Aspirin; Coronary Vessels; Humans | 1986 |
Aspirin for unstable angina?
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation; Pro | 1986 |
Altered intraplatelet arachidonic acid metabolism during the acute state of unstable angina.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Arachidonic Acid; Arachidonic Acids; Aspirin; Bloo | 1987 |
Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Combinatio | 1988 |
[Effect of various drugs on rheological properties of the blood and hemostasis in patients with unstable stenocardia].
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Aspirin; Blood Viscosity; Female; Hemostasis; Humans | 1987 |
Dissolution of angiographically detected intracoronary thrombus for unstable angina pectoris after aspirin therapy.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angiography; Aspirin; Coronary Disease; Coronary Thrombosis | 1987 |
Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes.
Topics: Angina, Unstable; Animals; Aspirin; Coronary Circulation; Coronary Disease; Coronary Vasospasm; Dogs | 1986 |
[Effect of hemosorption and the separate and combined use of obsidan, trental and colpharit on rheological and hemostatic properties of the blood in patients with unstable stenocardia].
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Aspirin; Blood Viscosity; Combined Modality Therapy; | 1986 |